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Tiffany W. Guo
There is a disproportionate burden of disease (measured in daily-adjusted life years, or
DALYs) in low-income countries. Much of this disparity is due to infectious diseases: 53%
of DALYs in Africa are due to infectious diseases, compared with only 3% in the American
continents. This disparity is largely due to differences in electrical and transport infras-
tructure as well as access to skilled personnel and monetary resources. Current diagnostic
solutions are primarily designed for high-resource settings and therefore these solutions can-
not be easily translated to a lower-resource setting. In order to tackle this health disparity,
new solutions must be designed specifically for a lower-resource setting. In this dissertation,
we take a translational approach to engineering appropriate diagnostics for resource-limited
settings. First, we develop a handheld smartphone accessory to perform an assay similar to
enzyme-linked immunosorbent assay (ELISA), traditionally a laboratory-based test. In 15
minutes, it provides an objective diagnostic readout important for minimal training, while
using an average of 1.6mW of power and costing only $34. We further develop the device to
provide a quantitative hemoglobin measurement simultaneously with an HIV immunoassay,
for use in antenatal care screening. The multiplexing two assay types that are clinically
relevant has the potential to streamline workflow. While specifications can be demonstrated
in the laboratory, the true test of the device must be performed in the field. We brought our
smartphone accessory to three health centers in Kigali, Rwanda to be used by healthcare
workers with no prior experience in ELISA. After a short 30 minute training, the healthcare
workers were able to obtain diagnostic results comparable to other immunoassays run un-
der field conditions. With a simple and user-friendly design, we sought to further expand
the usage of our device as a self-testing device, having patients test themselves. Lastly, we
explore manufacturable thermoplastics as a material for a microfluidic diagnostic for nucleic
acid detection. The sum of this work aims to gain insight into methods of design, testing,
and implementation of translational design.
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CHAPTER 1. INTRODUCTION 1
Chapter 1
Introduction
There is a disproportionate burden of disease (measured in daily-adjusted life years,
or DALYs) in low-income countries. Much of this is concentrated in the African continent,
particularly in sub-Saharan Africa (Figure 1.1). Much of this disparity is due to infectious
Figure 1.1: Regional daily adjusted life years in 2012. Adapted from [1].
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diseases: 53% of DALYs in Africa are due to infectious diseases, compared with only 3% in
the American continents. The main culprits causing disease are human immunodeficiency
virus (HIV), malaria, tuberculosis, and diarrhea. Almost all of these diseases have been
eradicated in developed countries, and have definitive diagnoses and established treatment
regimens.
Many of the diagnostic methods for infectious diseases have been developed with
high-resource settings in mind. However, developing countries face vastly different conditions
(Figure 1.2). High-income countries have an average of 7.4 health care personnel (HCP) per
1000 population, by comparison, low-income countries have an average of 1.1 HCP per 1000
population. Further, the HCP in low-income countries is skewed towards nurses, pharmacists,
and community health care workers, with much fewer physicians. Additionally, low-income
countries have about 35% electricity coverage (compared with 100%) making devices with
large energy consumption irrelevant. Low-income countries have about 19% of their roads
paved, (in comparison with 87%), making travel to health centers more difficult and time
consuming than otherwise possible (Table 1.1).
Figure 1.2: Differences in laboratory settings between high-resource (left) and low-resource
(right) settings.
CHAPTER 1. INTRODUCTION 3
High-income countries Low-income countries
Doctors and Nurses [2] 7.4/1000 population 1.1/1000 population
Nurse-to-doctor ratio [2] 2.5 (Nurse:Doctor) 5.2 (Nurse:Doctor)
Electricity Coverage [3] 100% 35%
Transport infrastructure [4] 87% paved roads 19% paved roads
Poverty levels [3] no data 34% on <$2/day
Table 1.1: Comparison of access to health resources in high-income and low-income coun-
tries.
Because of these differences, most solutions developed for high-resource settings can-
not be directly transplanted to low-income countries. To tackle the persistence of infectious
diseases in these regions, medical solutions must be engineered specifically to work in these
settings (Table 1.2). 1) Sensitive and specific. Any diagnostic test must provide informa-
tion with enough sensitivity and specificity that it provides clinically useful and actionable
information. The needed sensitivity and specificity values depend on the current availabil-
ity of other diagnostic tests in the region. A diagnostic with less optimal sensitivity and
specificity may provide value if it can be disseminated beyond the reach of centralized diag-
nostics [5]. 2) Minimal training for operation. This diagnostic ideally would be able to be
run without significant training or complicated equipment, such that the solutions are not
limited by skilled personnel or technical infrastructure. 3) Low/no power usage. A diagnos-
tic with low/no power usage would be significantly more accessible in a low-income country.
Stable electricity infrstructure is rare, particularly when moving outside major city regions,
and reducing dependency on this infrastructure would free a diagnostic device to be used
anywhere. 4) Portable and robust. Rapid, and robust designs enable diagnostics to travel
easily to patients. In developing countries, health-care infrastructure is sparse, and many
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Condition Design Constraint
High incidence of treatable disease Sensitive and specific diagnosis
Low availability of trained health personnel Minimal training for operation, sample col-
lection, simplify workflow
Low electricity coverage Low/no power usage
Poor transportation infrastructure Portable, rapid, robust
High poverty levels Low-cost, cost-effective implementation
Table 1.2: Design constraints for a low-resource setting.
citizens have to travel hours just to access basic health needs. This travel requires time,
money, and opportunity cost, and a diagnostic that can be moved outside of traditional
healthcare infrastructure is very useful. 5) Cost-effective implementation. The diagnostic
must be cost-effective to implement in a low-income country. Most healthcare services are
paid for through the government and through international aid agencies, so each intervention
adopted is additionally tasked to provide value at a population level.
Microfludics has long been touted as an ideal solution for point-of-care diagnostics for
low-resource settings [6, 7]. By miniaturizing assays into microscale channels, reactants are
brought closer to the reaction surface, thus decreasing overall reaction time. Miniaturizing
also allows for a small footprint and lower reagent and sample consumption, allowing for
a lower cost design. Channel structures within a microfluidic cassette can be designed to
automate many manual steps - enabling use by less technical users. Despite the vast aca-
demic efforts in developing these technologies, very few of these have been translated to the
field. Many innovations developed in academia often only focus on one part of the diagnostic
procedure (e.g. sample preparation, fluid control, signal detection) [8]. While these can be
important innovations, they can only become useful by integrating every step together into
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a diagnostic system that truly fits the design constraints of a resource-limited setting. It
is therefore important to design for integration and translation from the very beginning of
a design concept. Intricate understanding of how different diagnostic components interact
will facilitate a more translational design. For example, developing a silver-amplification
detection read-out enables low-cost detection optics [8]. Furthermore, testing integrated
innovations in a truly resource-limited setting provides essential insights into further inno-
vations necessary for translational designs.
1.1 Overview of work
The following is an overview of the work:
Chapter 2: Developing a smartphone accessory for performing immunoas-
says in low resource settings. We sought to replicate a laboratory-quality immunoassay
at the point of care. While paper-based rapid diagnostic tests are widely used in devel-
oping countries, they are subject to user interpretation and limited assay complexity. As
smartphones are growing in popularity worldwide, we leveraged this increasingly ubiquitous
computational tool to expand diagnostic availability. We designed a robust, integrated, and
setting-appropriate smartphone accessory that can perform a triplex antenatal care panel
(HIV, syphilis treponemal, and syphilis non-treponemal markers) on fingerprick whole-blood.
My role in this work was the design and development of the smartphone accessory. This
work was published - Guo T, Laksanasopin T, Nayak S, Sridhara AA, et. al. (2015) A
smartphone dongle diagnosis of infectious disesaes at the point-of-care. Science Translational
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Medicine 7, 273re1-273re1.
Chapter 3: Measuring hemoglobin concentration and detection of HIV
antibodies with a smartphone accessory. Here, we utilize the smartphone accessorys
precise optics in a quantitatively diagnostic manner, for the measurement of hemoglobin
concentration. Anemia affects almost half of the world’s pregnant women, and is a critical
part of of a complete antenatal care screening. We integrate the measurement within the
existing immunoassay, demonstrating no effect on the diagnostic capability of the immunoas-
say. Further, we add no additional time to the assay, while adding a critical and clinically
relevant laboratory parameter for antenatal care screening. My role in this work was the
design, development, and testing of this device. This work was published - Guo T, Patnaik
R, Kuhlmann K, Rai AJ, Sia SK. (2015) Smartphone dongle for simultaneous measurement
of hemoglobin concentration and detection of HIV antibodies. Lab Chip 15, 3514-20.
Chapter 4: Demonstrating use of the smartphone dongle at the point of
care We sought to understand the diagnostic accuracy of the smartphone dongle with in-
tended end-users: healthcare workers with no experience in laboratory-based immunoassays.
We tested this device in Kigali, Rwanda, operated by healthcare workers with no previ-
ous experience in laboratory-based enzyme linked immunoassays (ELISAs). After a short 30
minute training, healthcare workers were able to perform the test and demonstrated 92-100%
sensitivity and 79-92% on a triplex immunoassay panel for antenatal care. My role in this
work was the field testing of the device and data analysis. This work was published - Guo
T, Laksanasopin T, Nayak S, Sridhara AA, et. al. (2015) A smartphone dongle diagnosis
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of infectious disesaes at the point-of-care. Science Translational Medicine 7, 273re1-273re1.
Chapter 5: Expanding HIV diagnosis outside the clinic with a smartphone
accessory. Here, we sought to understand how our simple-to-use diagnostic device could
further expand the reach of diagnostics through self-testing. With only a short 11 minute
training, participants (patients at a clinic in Kigali, Rwanda, with no prior health training)
were able to complete steps necessary to perform our test. The smartphone has the potential
to be used, not just as a processor and display mechanism, but as an interactive user-
interface and a point of connectivity to the healthcare system. We tested both the usability
and accuracy of our device in the hands of subjects with no prior health-training, as well
as assessed their overall attitudes towards adopting self-testing for HIV and beyond. This
demonstrates the potential for well-designed devices to expand access to anybody with access
to the device. My role in this chapter was the design and development of a more user-friendly
smartphone dongle, field trial design and implementation, and data analysis.
Chapter 6: Selecting materials for an amplification module for use in
molecular diagnostics. Molecular diagnostics is a second major class of assays for blood-
based infections. Much of the literature in lab-on-a-chip nucleic acid amplification utilizes
glass, silicon, and PDMS in highly complex devices that ultimately do not yield mass man-
ufacturable designs. Here, we sought to understand the material characteristics of poly-
carbonate, an injection-moldable thermoplastic, as a medium for amplification chambers.
Testing and understanding manufacturable materials and design at the research stage en-
ables innovations that can more easily be translated into industry. My role in this chapter
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is the design, manufacture, and testing of these plastic chambers.
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Chapter 2
Performing immunoassays at the
point of care with a smartphone
accessory
2.1 Background
In this chapter, we seek to develop a portable and setting-appropriate point-of-care
diagnostic device to perform multiplex immunoassays. Our principle application is diagnosis
of HIV and syphilis for antenatal care screening. Both have definitive treatments available
that can prevent transmission to the child and reduce morbidity for the mother. For HIV, a
single dose of nevirapine during labor and delivery will reduce transmission to the child, and
prompt initiation of antiretroviral treatment reduces morbidity for the mother. For syphilis a
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single dose of penicillin will both cure the mother and reduce incidence of congenital syphilis,
which can otherwise lead to low birth weight, congenital abnormalities, or even death of
the infant. Easily accessible and reliable diagnosis is critical in reducing transmission and
sequelae of these diseases.
2.1.1 Current diagnostic methods
In a low-resource setting the most common method to diagnose HIV is through a
lateral flow-based rapid diagnostic test (RDT). Each test consists of a series of dense mem-
branes: first a sample pad to receive the blood sample, next a conjugate pad impregnanted
with gold-labeled reporter antibodies. next along strip with two lines of immobilized capture
antibodies (one test and one control), and lastly an absorbent pad to drive capillary flow.
When a sample is introduced on one end of the strip, it will travel through the conjugate pad
and disease-specific antigens will bind to gold-labeled reporter antibodies. This gold-antigen
conjugate will wick through the test strip via capillary action and bind to the immobilized
capture antibody, and the collection of gold nanoparticles creates a visible red line (Figure
2.1). Rapid diagnostic tests are commonly used because they require no power to oper-
ate, have a long reported shelf-life and are simple to operate and interpret. While simple
in principle, operating the device still requires significant training (5 days per WHO) [9].
Variables such as amount of light when visualizing the lines, amount of time passed before
interpreting lines, and flatness of the test surface can all affect accuracy of results. Faint
test lines are recommended to be interpreted as positive, though 43% of them can actually
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be false positives, and can decrease specificity to 90% [10]. Further, while seemingly robust,
RDTs are still sensitive to high heat and humidity (common in many low-income countries),
and sub-optimal storage conditions can increase rate of invalid test strips from 10% to 17%
[11]. In one study of diagnostic tests, strong positive and negative results were interpreted
correctly only 78.7% and 79.9% of the time respectively. Further, weak positive results were
interpreted correctly only 26.7% of the time [12].
Figure 2.1: A) Schematic diagram of a rapid diagnostic test, B) Image of rapid diagnostic
test with positive and negative results [6].
Given the drawbacks of RDTs, the gold-standard for immunoassay diagnosis is still
the laboratory-based enzyme-linked immunosorbent assay (ELISA). In this assay, the a
binding-antigen or antibody is immobilized on a plastic surface, typically the bottom of
a 96-well plate. Sample is introduced into the well, and disease-specific antibodies bind to
the plastic surface. Next, enzyme-linked secondary antibodies are added, and the well is
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washed several times with buffer to reduce non-specific binding. Lastly, the enzyme sub-
strate is introduced into the well, and any enzyme present due to target-secondary antibody
binding will show a proportional color change, which is quantified in a spectrophotometer.
While very similar in principle to the lateral flow immunoassay, the ELISA has 3 major
advantages: 1) multiple wash steps to reduce non-specific binding, 2) amplification of pos-
itive signal with enzyme-substrate reaction, and 3) objective and quantitative detection of
signal. This test takes 2 hours, requires large, expensive machinery (up to $18,000 [13]),
highly-trained personnel to operate, requires steady power supply, and is designed for high-
throughput centralized laboratories. Given the difficulty of accurately interpreting weak
positive test lines, many studies recommend confirmation testing of weak positives with the
ELISA [10, 14]. However, this test is difficult to implement at the point-of-care in low-income
countries without steady electricity and availability of trained personnel.
Active syphilis infection, caused by Treponema pallidum, is diagnosed with two tests.
The first is a non-treponemal specific test, called rapid plasmin reagin (RPR), which detects
the presence of anti-cardiolipin antibodies. This indicates the presence of active syphilis
infection, however, is not very specific for syphilis infection and is also elevated in preg-
nancy, lupus, and other conditions. In this test, serum or plasma is placed onto the RPR
card, which contains cardiolipin and charcoal (visual enhancer). The sample and card are
incubated on a platform shaker for 8 minutes. If anti-cardiolipin antibodies are present,
they will coagulate creating visual black clumps. RPR kits are low-cost, but still require
refrigeration, trained personnel to perform and interpret, and some laboratory infrastructure
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(platform shaker, pipettes). The second test is a treponemal specific test, such as Treponema
pallidum hemagglutination assay (TPHA). While detecting treponemal-specific antibodies is
more specific for syphilis than RPR, these antibodies remain detectable even after curative
treatment is given, and therefore does not indicate an active syphilis infection. In this assay,
red blood cells sensitized with antigens to T. pallidum are mixed with sample and incubated
for 2 hours. If treponemal-specific antibodies are present, the sample will show visible ag-
glutination. TPHA utilizes 96-well plates, significant time, and requires precise pipetting,
and training to interpret the results.
Recently, several manufacturers (Chembio, SD Bioline, and MedMira) have developed
dual HIV/treponemal syphilis tests, a testament to the demand for this combination testing.
However, as lateral flow-based tests, these tests are subject to the same disadvantages of
other lateral flow-based tests. Further, no triplex test containing HIV, syphilis treponemal,
and syphilis non-treponemal currently exists on the market. Countries will chose either a
treponemal or non-treponemal test for syphilis screening based on cost and prevalence in
country, however, it is clear both test provide information critical for accurate diagnosis of
active syphilis infection.
2.1.2 Microfluidic immunoassay
Our group has previously demonstrated a microfluidic-based immunoassay that repli-
cates all the steps of a laboratory-based ELISA. In place of a 96-well plate coated with
disease-specific antigen, we used an injection-molded microfluidic chip about the size of
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a credit card with disease-specific antigen coated on a series of microfluidic meanders as
the test zones. Briefly, each detection zone is treated with capture proteins and when the
serum/plasma sample flows over each zone followed by signal-development reagents (gold-
labeled antibodies, washes, and silver development solution), such that the concentration
of analyte captured on each zone corresponds to the optical density of silver enhancement
(Figure 2.2). In place of an automated robotic arm or skilled personnel for washes, reagents
Figure 2.2: Schematic diagram of immunoassay steps.
were loaded in sequence in a polyethelene tube with air gaps in between. A 60-mL syringe
was set to the 20-mL line and attached to the microfluidic channel outlet, then pulled to
30-mL line to create a relative negative pressure of -30 kPa. The whole set-up was extremely
portable and required only the microfluidic cassette, reagents in a tube, syringe, and portable
reader to measure the optical density of the zones (Figure 2.3). On 67 serum and plasma
samples, this system demonstrated 100% sensitivity and 95% specificity to diagnose HIV,
and 94% sensitivity and 76% specificity for a treponemal-specific syphilis test [15]. This di-
agnostic system incorporates all the advantages of the gold-standard ELISA test: 1) washing
for non-specific binding, 2) signal amplification (in this case through silver development on
gold-nanoparticles), and 3) objective optical detection.
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Figure 2.3: A) Image of plastic injection molded microfluidic cassette. B) Schematic
diagram of automated reagent delivery to each microfluidic meandering zone (depicted at
the bottom) via pre-loaded polyetheylene tubing at the channel inlet and syringe-generated
vacuum at the microfluidic outlet [15].
Next, our lab developed a portable integrated device to run this test. The microfluidic
chip inserts into a 24 x 11 x 11 cm device, and the chip aligns with a miniaturized version of
the optical density reader and a micro-vacuum at the microfluidic outlet. The whole device
is powered through a 9V battery, with an average power consumption of 0.62 W (Figure
2.4). By comparison, a mobile phone uses 0.75 W and a laptop computer uses about 20-60
W. The device sought to move beyond diagnosis and integrate this information into a health
system, by building in capability to send diagnostic results through GSM and satellite [16].
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Figure 2.4: Schematic diagram (A) and image (B) of a portable integrated device for point-
of-care microfluidics including fluid handling, signal detection, and data communication
modules [16].
2.1.3 Mobile phone revolution
Over the past 15 years, mobile phone usage has skyrocketed, which has been partic-
ularly revolutionary in low-income countries. In a survey of 7 African countries, cell phone
ownership in Africa ranges from 65-89% rivaling 89% cell-phone ownership in the US. Mo-
bile devices have been able to circumvent need for infrastructure in low-income countries:
approximately 97% in the surveyed African countries do not have a landline, compared with
40% in the United States [17]. M-PESA and MTN mobile money have revolutionized mobile
money transfer, providing banking to 18 million users, reducing the use of cash, and in-
creasing financial security. Information dispersal through SMS has enabled math education
thorugh instant messaging beyond the classroom as well as farming tips for dairy farmers
to increase their overall productivity, thus increasing revenue. Beyond basic texting, over
half of new mobile broadband subscriptions are in developing countries, the fastest growing
region [18].
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In low-income countries, mobile phones uptake has skyrocketed to match US rates
in some countries, and smartphone adoption is quickly following [19, 20]. Mobile phones
in low-income countries have been critical in expanding access banking, education, and
other services that have typically relied on infrastructure. Smartphones are increasingly be-
ing adapted for health diagnostics, the most common applications have leveraged individual
components and functions, such as cameras [21], data communication [22], and data process-
ing [23]. Less prevelant are smartphone accessories that replicating any complete diagnostic
assay performed in clinical laboratories [16, 24].
2.1.4 In this chapter
In this chapter, we sought to build on previous work in miniaturizing diagnostics
hardware [16, 25, 26] for the rapid point-of-care diagnosis of HIV and syphilis. While RDTs
have become the mainstay of immunoassays in low-resource settings, they are limited assay
complexity, multiplexing capability, and still require user training and interpretation. The
gold-standard for immunoassays is still the enzyme-linked immunosorbent assay (ELISA):
a large power-heavy benchtop machine which requires significant training to operate. We
therefore sought to engineer all the capabilities of a bench-top enzyme-linked immunosorbent
assay (ELISA) instrument into a small diagnostic accessory, a dongle, that attaches to a
smartphone.




Figure 2.5: Left panel shows a reagent cassette (top layer) which contains pre-stored
reagents (washes (yellow), silver A and B (blue and green)) and the test cassette (bottom
layer) contains five detection zones. Reagents are numbered in the order they flow through
the test cassette. Right panel shows sequence of flow through test cassette. From the inlet,
fluids move through each detection zone sequentially, then flowing into a waste pad where
blood sample and reagents are collected without any fluids exiting the chip. The power-free
vacuum chamber connects to the cassette outlet, drawing fluids from the inlet towards the
waste pad.
The smartphone dongle was designed to interface with a disposable injection-molded
microfluidic test cassette with pre-loadable reagent cassette (Figure 2.5 and Table 2.1). Each
test zone is spotted with disease-specific antigens, and will darken in the presence of disease-
specific antibodies. These test zones are aligned to LEDs and photodiodes within the dongle
to quantitatively assess zone darkness. The dongle connects to the microfluidic cassette
outlet to draw the sample and subsequent reagents through the test cassette. The integrated
reagent cassette converted the wash plugs into an integrated These injection molded plastic
cassettes are made from cyclic olefin co-polymer (COC), designed and obtained through
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OPKO Diagnostics. The protein surface modification procedures and device for this work
were developed at Columbia.
2.2.2 Dongle fabrication
Custom-printed circuit boards were designed in Altium and printed from PCB Uni-
verse. A bill of materials and the circuit diagram (Figure 2.6) are provided.
Figure 2.6: Circuit diagram of dongle. (A) Power harvesting from audio jack connector, (B)
MSP430f1611 connections, (C) LED circuit, and (D) photodiode with signal amplification.
In (C) and (D) only one example circuit is shown, but analogous circuits are connected to
LED 2-5 and PHOTO 2-5 respectively.
LEDs and photodiodes were precisely aligned with the cassette slot so that testing
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Table 2.1: Bill of Materials for smartphone dongle






Audio connector Amazon n/a 1 1.000 1.00
Transformer Coilcraft LPR6235 1 0.770 0.77
MOSFET, N-Channel Mouser 522-ZXM61N03FTA 2 0.210 0.42
MOSFET, P-Channel Mouser 522-ZXM61P03FTA 2 0.210 0.42
Schottky diode Digikey DFLS120LDICT-ND 1 0.180 0.18




Digikey 296-22900-ND 1 10.310 10.31
Oscillator Digikey SE2413CT-ND 1 0.770 0.77





Digikey 67-2194-1-ND 5 0.190 0.95
Photodiode Digikey 475-2659-1-ND 5 0.560 2.80
Capacitor, 0.1 F Digikey 1276-1443-1-ND 10 0.003 0.03
Capacitor, 1 F Digikey 1276-1010-1-ND 1 0.009 0.01
Capacitor, 2.2 F Digikey 1276-1183-1-ND 1 0.020 0.02
Capacitor, 4.7 F Digikey 1276-1056-1-ND 1 0.049 0.05
Capacitor, 10 F Digikey 1276-1451-1-ND 3 0.140 0.42
Resistor, 27 Digikey 311-27JRCT-ND 5 0.002 0.01
Resistor, 1 k Digikey 311-1.00KLRCT-ND 1 0.003 0.00
Resistor, 10 k Digikey 311-10KJRCT-ND 1 0.002 0.00
Resistor, 100 k Digikey 311-100KJRCT-ND 1 0.002 0.00
Resistor, 300 k Digikey P300KGCT-ND 5 0.004 0.02
Resistor, 5.1 M Digikey 541-5.10MHDKR-
ND
1 0.017 0.02
10 pin flat flexible cable
(FFC) connectors
Digikey HFN410CT-ND 3 0.840 2.52
10 pin FFC Digikey WM14313-ND 1 2.020 2.02
Printed circuit board
(PCB) Mainboard
PCB Universe Custom 1 0.420 0.42
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zones aligned without manual effort. One-mm pinholes made of 1-mm thick black Delrin
(McMaster-Carr) were aligned above each photodiode to prevent stray light. The dongle
casing was designed in SolidWorks and printed in-house (Objet 24 3D-Printer, Stratasys).
Vacuum chamber was created with a one-way umbrella valve (Minivalve), a rubber bulb from
a 140-mL syringe (Becton Dickinson), and a conical spring (Century Spring Corp) inside to
aid re-expansion. Silicone rubber o-rings and sheets (McMaster-Carr) were used to connect
to outlet and seal the venting port.
2.3 Results
We developed a smartphone accessory that could run a full laboratory immunoassay
that could be implemented in low-resource settings with minimal training (Figure 2.7).
Figure 2.7: An image of the dongle with a microfluidic cassette connected to an iPod touch.
2.3.1 Power-free fluid flow
Access to reliable power is limited in develping countries, and an ultra low-power
design that is independent from the power grid greatly increases the accessibility of an
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innovation. Syringe pumps used in typical microfluidic-based set-ups take up to 18 W
of power and are fully dependent on grid-power. Our group has previously demonstrated
a device with integrated microvacuum, which still utilized about 3 W, and 27% of total
power [16]. Some power-free methods have been developed, including manufacturing a pre-
packaged vacuum source within the microfluidic chip [27], however this would add additional
complexity and cost to manufacturing as well as limit shelf-life.
We eliminated this by developing a ”one-push vacuum”, where a user mechanically
activates a negative-pressure chamber to move a sequence of reagents pre-stored on a cassette.
Our setup mechanically generates the vacuum source at the time of assay; this procedure
is durable and repeatable (similar to a bulb for a manual sphygmomanometer), requires
little user training, and utilizes the familiar act of pushing a button. The simple vacuum
Figure 2.8: Schematic diagram of dongle highlighting a power-free vacuum generator. (A)
When the user pushes the rubber bulb, air exits out the one-way valve, (B) the spring aids
the bulb in re-expansion, creating a relative vacuum that pulls all the reagents through the
microfluidic channels.
chamber was created with a rubber bulb, with one port connected to the assay cassette
outlet and one port to a silicone one-way valve. When the bulb is depressed, air exits out
the one-way valve, and a spring aids the bulb in re-expansion, creating a negative pressure
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within the chamber that pulls liquids through the channels (Figure 2.8). Each test included
a microfluidic cassette with reagent holder on top and an antibody holder with lyophilized
gold (Figure 2.5). Once the antibody holder was attached, the microfluidic cassette and
reagent holder were connected. When the microfluidic chip was fully inserted into the dongle,
the microfluidic output connected with the vacuum chamber sealed with a rubber o-ring.
The user initiated flow by pressing the bulb, and reagents flowed over the sample zone
in sequence: sample, gold-labelled secondary antibodies, and washes. The user was then
prompted to slide the toggle to seal the venting port, which initiated the flow and mixing
of two silver developing agents. Despite being a manual process, the total flow times for a
Figure 2.9: User-activated negative pressure-driven flow. Average time to flow a total
sequence of 6 washes: two 2-µl washes of 0.05% Tween-PBS and four 2-µl washes of DI
water, are shown. Two of the three users were not device developers (i.e. unfamiliar with
the device). Data are averages, ± 1 SD (n = 4). n.s., not significant, one-way ANOVA (P
= 0.149).
6-wash sequence were consistent between three users, with an average of 119 seconds (Figure
2.9).
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2.3.2 Precise optics
Subjective read-out is one of greatest limitations of the rapid diagnostic test; an objec-
tive read-out can effectively reduce training burden for accurate diagnostic test operation.
The ELISA reader provides an objective diagnosis, however the large, benchtop device is
reliant on steady power supply, requiring 100-240 V AC, using up to 1.2 A.
In the dongle, each testing zone was sandwiched between an LED and a photodiode
with a signal amplifying circuit, each requiring very low power. The light intensity through
each zone was measured before (I0) and after (I) silver development, and optical density
(OD) is calculated by:
OD = −log(I/I0)
Gold-labeled secondary antibodies captured on the zone initiated silver development, dark-
ening the zone, creating a change in light intensity sensed by the photodiode. Based on an
optical density cut-off point, a particular test could be determined as positive or negative,
and clearly displayed to the user.
We designed the dongle so that power was only consumed during optical density
readings (8.5 mW, 8 sec) and during information transfer back to the smartphone (1.5 mW,
8 min); no power was consumed by the dongle while sample and washes were flowing (Figure
2.10). Over a 15-minute assay, the dongle had an average power consumption of 1.6 mW,
or 0.22 mWh per test. By comparison, a typical smartphone uses 751 mW on a 3G network
and 17.5 mW on standby mode [16], and a laser pointer uses approximately 1-5 mW [28].
Using an Apple iPod Touch (4th generation) to power the dongle, we found that each run
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Figure 2.10: Power consumption of dongle (black) and OD of the HIV zone (red) during
the assay. High OD is observed while whole blood flows through the zones, with low OD
during gold-labeled antibodies (Au-Ab) and washes. At minute 7, OD increases as silver
develops.
consumed about 2.4% of the battery, allowing 41 runs to be made on a single charge (note
that newer generations of smartphones can hold more charge).
2.3.3 Audio jack powering and signal transmission
With such low power consumption by the dongle, we were able to implement a second
innovation to remove the need for a battery: using the audio jack for transmitting power and
for data transmission, as demonstrated by Kuo et al [29]. The audio jack connection (3.5
mm, 4 lead) has remained ubiquitous and standardized among smartphones, which allowed
our dongle to be compatible with the growing variety of mobile phones and tablets. Here,
a 19-kHz audio signal was sent from the iPod Touch through the audio jack to the dongle,
and converted into a stable DC 3.0 V. The dongle had no internal battery and used only
the power delivered by the audio signal. After light intensity at each zone was measured,
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the microcontroller, MSP430f1611 (Texas Instruments), sent the information through the
microphone line via frequency-shift keying (FSK). The decimal integer was converted into
binary and each digit was sent as either 1600 Hz (”1”) or 800 Hz (”0”) at a rate of 1 bps
(Figure 2.11). Signals were decoded by the phone with non-coherent FSK demodulation:
samplings of each incoming signal were correlated with sine/cosine waves of 1600 Hz and
800 Hz, and correlations were added to determine if a high or low frequency had been
transmitted (Figure 2.12).
Figure 2.11: The smartphone’s audio jack was used for powering the dongle and signal
transmission.
To test the accuracy of the signal, we programmed the microcontroller to send a pat-
tern of alternating ”1” and ”0”, or high and low frequency signals, respectively. The power
is only consumed by the device for 8.5 minutes, to take intensity readings and transmit
information. During the test, the custom smartphone application (”app”) on the phone con-
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Figure 2.12: Non-coherenst FSK demodulation.
verted the photodiode signals to absorbance units, which could be reported as ”positive” or
”negative” when above or below, respectively, a preset cut-off value. Our initial implemen-
tation was focused on fidelity of signal, but signal transmission can be sped up in the future.
To test the accuracy of the signal, we programmed the microcontroller to send a pattern of
alternating ”1” and ”0”, or high frequency and low frequency signals. We observed 100%
accuracy of 12,160 bits tested.
The power harvested from the audio jack was stable and sufficient for reliable optical
density (OD) measurements compared with a benchtop analyzer. In order to compare the
OD readings of the iPod powered dongle to the benchtop analyzer from OPKO Diagnostics,
an HIV seropositive whole blood sample was tested (n=3) on the assay platform, with light
intensity measurements taken by both devices for direct, head-to-head comparison. OD
values were calculated on three detection zones for analysis: negative control, r17 target,
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Figure 2.13: Comparing readings from the dongle with readings from the benchtop ana-
lyzer. An HIV-positive whole-blood sample was run in triplicate, where measurements were
taken with the iPod audio jackpowered dongle and the benchtop analyzer (OPKO Diag-
nostics, without the temperature-control system, in order to mimic the dongle) reading the
same cassette. Data are averages 1 SD (n = 3). n.s., not significant, two-tailed Students
t-test.
and HIV target to show a range of signal readings. For the target and positive-control zones,
there was no significant difference in OD measurements taken by the dongle and benchtop
analyzer (Figure 2.13). (The negative-control zone showed a small but significant difference
(p = 0.03).)
2.3.4 User-friendly app interface
We designed a user-friendly app in iOS for use on an iPod Touch to assist in assay
operation, power the device to take intensity readings, and demodulate the FSK signals sent
by the device (as described above). The app provides step-by-step directions with pictures to
assist the user through steps necessary to perform the assay. Once the assay was completed,
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the results were not displayed until the user pressed ”Show Results” (Figure 2.14). This
allowed the user to ensure privacy before revealing any sensitive information on the screen.
The Results page could be clearly indicated a positive or negative diagnosis for each of the
three tests performed using preset cut-off values. The app also saved the raw data, diagnosis,
time and date of testing, and patient ID number for review at a later time. An additional
passcode can be required for results viewing, if increased security is needed. The smartphone
interface has the potential to reduce training burden and enhance overall user accuracy. In
one study of untrained users, even when provided with instructions (which were reviewed by
88% of participants), only 25% of participants performed all steps correctly [12].
2.4 Discussion and Conclusion
While many advances in the literature purport to design for resource-limited settings,
solutions cannot be developed in isolation. Effective, careful integration of each solution is
the critical step to translate these innovations to meet the design criteria of low-power, low-
training burden, and robust devices. First, we dramatically reduced the power consumption
by 1) eliminating a power-consuming vacuum pump and 2) using simple optics with precise
measurements. This enabled us to power the whole device through power harvested from the
smartphone audiojack to eliminate the dependency on batteries or reliable power sources.
Next, this device was designed to be small and compact enough to be handheld and ultra-
portabe. Using commercially available electronic components with an injection-moldable
case, our device would have a manufacturing cost of $34 USD, in comparison to $18,450
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ELISA Smartphone dongle
Electronics plate reader $8,850 custom PCB $31
Communications data acquisition cable n/a FSK via audio jack n/a
Mechanical plate washer $9,600 $3
$18,450 $34
Total +computer +smartphone
Table 2.2: Table comparing the price of an ELISA and a smartphone dongle
USD for typical ELISA equipment (Table ??). The integrated engineering choice allowed
for a device to be significantly more portable and user-friendly than the laboratory-based
ELISA (Figure 2.15).
This dongle takes a step towards coupling microfluidics with advances in consumer
electronics. The hardware of the dongle exhibits characteristics similar to familiar consumer
electronics devices through a number of technical innovations: low power (using a power-
free, continuous-flow vacuum and requiring no power), durable components (using LEDs
and photodetectors), and portability. Our system generates a reliable, repeatable vacuum
at the time of the assay, while keeping the consumables simple to manufacture, building
on previous methods to simplify the fluid movement steps (such as vacuum [15] and degas-
driven flow [30]). The most important feature behind a ”plug-and-play” experience is the
reduction of manual steps, enabled by integrating advances in fluidics, mechanical, optical,
and electronic components. To enhance the user experience, we built a touch-activated
pictorial software interface that allowed for training in 30 minutes, a step-by-step software
guide on the smartphone contemporaneous with assay operation, and reporting of results
(yes/no or quantitative titers) without user interpretation. As a result, patients expressed
satisfaction with the dongle, citing the 15-minute turnaround time as the biggest benefit, as
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a third of patients wait more than 2.5 hours to receive their results (personal communication
with patients). Overall, the combined hardware, software, and microfluidic specifications
suggest that new consumer-oriented medical devices are on the precipice of moving beyond
glucose monitoring, vital signs, and wellness into clinical diagnostics.
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Figure 2.14: Step-by-step illustration of dongle testing. (A) User starts the application
and enters patient ID number. (B) User mixes 1 l of whole-blood sample with 9 l of diluent
and inserts the cassette into the dongle. (C) User presses the bulb fully to initiate vacuum,
places 2 l of the mixed sample into the cassette and attached the antibody holder into the
cassette. (D) The application displays step-by-step instructions for user to follow, as well as
remaining assay time. (E) After completing the assay, user selects View Results to display
test results. Another passcode could be added at this step for an extra security and privacy.
(F) Screen displays results for each disease marker. The app can be set to show absorbance
values or positive and negative diagnoses, in the study we displayed absorbance values. User
clicks Finish button to prompt back to the first screen for the next test. At this point, the
option to transmit test results via cloud or short message to a predesignated email address
or phone number could be incorporated.
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Figure 2.15: Photograph of smartphone dongle next to ELISA, approximately to scale.
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Chapter 3
Integrating hemoglobin measurement
with immunassays on a smartphone
accessory
3.1 Background
Screening for low hemoglobin concentration, or anemia, is critical in antenatal care
[31–33], as untreated anemia in pregnancy can lead to pre-term delivery, low birth weights,
and increased risk of maternal and fetal deaths [34–36] (about 20% of maternal deaths are
due to anemia [37]). For pregnant women, the World Health Organization (WHO) defines
anemia as blood hemoglobin concentration less than 11 g/dL, and severe anemia as blood
hemoglobin concentration less than 7 g/dL [38]. Because the risk factors for anemia include
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pregnancy, micronutrient deficiencies, and infectious diseases, anemia is especially prevalent
in pregnant women in developing countries. In a 2005 WHO global study, 41.8% of pregnant
women in worldwide had anemia, with the highest prevalence in Africa (57.1%) and South-
East Asia (48.2%) [39].
Figure 3.1: Worldwide map showing years lived with disability (YLD) due to anemia [40].
Currently, the Hemocue Hb 201+ system is a widely used point-of-care device for
measuring hemoglobin concentration. Blood is drawn into a small microcuvette ($1.43)
through capillary action, and hemoglobin concentration is read by a portable device (580
cm3, 350 gm, $800) (Figure 3.2). Although it is relatively expensive, its accuracy, minimal
training requirement, and easily interpretable results make it attractive in resource-limited
settings over manual methods [41, 42]. Previous studies to further reduce per test cost
of hemoglobin measurement include a paper-based method (which required several manual
steps and a flat-bed scanner) [43] and a spectrophotometric device (280gm, 330 cm3, $400)
for measuring hemoglobin concentration on a paper substrate [44] (Figure 3.3). An ideal
device would be more compact, capable of performing multiplexed diagnostics, and offer the
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ability for data collection or connectivity to a centralized electronic medical record (EMR),
as these functionalities have been shown to improve healthcare delivery in resource-limited
settings [45].
Figure 3.2: Image of commercially available Hemocue device.
In addition to measuring hemoglobin concentration, it is important for pregnant
women to be screened for HIV infection [31–33]. If diagnosed in a timely manner, both
anemia and HIV can be effectively treated (with iron supplements and antiretroviral drugs,
respectively), allowing for dramatic improvements in health outcomes for both mother and
infant. We modified the smartphone accessory from Chapter 2 to simultaneously measure
hemoglobin as well. The immunoassay in Chapter 2 uses gold-labeled secondary antibodies
with silver amplification, so positive test zones are darkened and diagnosis is objectively
determined with low-power light-emitting diodes (LEDs) and photodiodes. We leveraged
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Figure 3.3: Image of a spectrophotometric device to measure hemoglobin concentration off
of a paper substrate [44].
this precise optical set-up to spectrophotometrically measure hemoglobin concentration. In
this format, HIV antibodies and hemoglobin concentration can be measured in the same
compact, user-friendly format, with no additional hardware.
3.2 Methods
3.2.1 Device Design
Our smartphone dongle (Figure 3.4A) has five optical detection zones (with four used
in this study) which aligned with the five microfluidic tests zones in the injection molded
cassette (Figure 3.4A). Each optical detection zone consisted of an LED and photodiode
pair with a 1 mm diameter pinhole of 1 mm thickness (Delrin, McMaster-Carr)(Figure
3.5). Optical detection zone 1 measured hemoglobin concentration and consisted of a 530
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Figure 3.4: Microfluidic system for simultaneous hemoglobin measurement and HIV anti-
body detection. (A) Photograph of smartphone dongle, as seen in Chapter 2. (B) Photograph
of microfluidic cassette with five testing zones. Zone 1 is dedicated to hemoglobin measure-
ment and zones 2-4 are dedicated to the HIV immunoassay (negative control, HIV-specific
zone, and positive control).
nm LED (Lite-on, Digikey) and a green-sensitive photodiode (Osram, Digikey). Optical
detection zones 2-4 measured the optical density of immunoassay zones and consisted of
a 636 nm LED (Lumex, Digikey) and a red-sensitive photodiode (Osram, Digikey). LED
control and photodiode readings were programmed into an MSP430f1611 microcontroller,
and photodiode readings were read out to a computer.
3.2.2 Red blood cell lysis
We tested the following blood lysis agents, as blood lysis is important for reproducible
hemoglobin measurements: 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS,
Sigma), Triton X-100 (Sigma), and sodium deoxycholate (Sigma). Each lysis agent was dis-
solved in 1x phosphate buffered saline (PBS) or deionized water at a range of concentrations,
8 µL of the solution was placed in a microcentrifuge tube, and solvent was removed using a
centrifugal evaporator. CHAPS was tested at 12, 24, 48 mM; Triton X-100 was tested at 1, 2,
4, and 10 mM; and sodium deoxycholate was tested at 1.25, 2.5, 5% (w/v). Concentrations
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Figure 3.5: Schematic diagram of fluidic and optical experimental set-up. Sample and pre-
loaded polyethelyene tubing with reagents enter through the inlet and are drawn through the
microfluidic channels with syring-generated vacuum. The optical detection zone consists of
an LED that illuminates the test zone with photodiode opposite to collect the light. When
hemoglobin or silver development is present in the channel, it absorbs the incident light,
reducing the light sensed by the photodiode.
were chosen based on previous publications [44, 46]. To lyse blood, 8 µL of whole blood
(collected within the past 3 days) was gently mixed in the microcentrifuge tube with the
lysis agent. The sample was drawn into the microfluidic cassette by negative-pressure driven
flow (-34 kPa). In this study, all fluid flow was generated by connecting a 60 mL-syringe
to the cassette outlet, and pulling the plunger from 20 mL to 30 mL, held in place by a
metal spacer between the plunger and the barrel. Each sample was observed in the microflu-
idic channels under 10x magnification on a bright-field microscope. Blood was considered
completely lysed if there were no visible red blood cells.
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3.2.3 Spectrophotometric determination of hemoglobin concen-
tration
To evaluate our devices ability to quantitatively measure hemoglobin concentrations,
we simulated a range of hemoglobin concentrations. Supernatant plasma was removed from
whole blood to concentrate the collected sample to 21 g/dL. The concentrated blood was
diluted with plasma from the same sample to generate hemoglobin concentrations ranging
from 0.0 to 21.2 g/dL. To measure the hemoglobin concentration of a sample, 2 µL of 0.05%
(v/v) Tween-20 in PBS was drawn through the microfluidic channel, and an initial intensity
reading is taken (I0(Hb)). Next, blood was lysed with CHAPS by pipette mixing and drawn
through the channel. A second intensity reading is taken while blood was flowing through
the channel (IHb)). In this study, all fluid flow was drawn into the microfluidic cassette
by negative-pressure driven flow (-34 kPa). Fluid flow was generated by connecting a 60
mL-syringe to the cassette outlet, and pulling the plunger from 20 mL to 30 mL, held in
place by a metal spacer between the plunger and the barrel. This has method previously
been shown to have repeatable incubation times (coefficient of variation <5%) [15]. Optical
density (OD) is calculated as:
OD = −log(I/I0)
The average of two readings from a Hemocue Hb 201+ was taken for comparison. Whole
blood was collected in EDTA tubes via standard venipuncture from healthy donors via an
IRB approved protocol.
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3.2.4 Simultaneous measurement of hemoglobin concentration and
HIV antibodies with lysed whole blood
Microfluidic test zones were prepared through direct adsorption as described in Sec-
tion 4.2.1. For these experiments, the test zones were prepared as follows: no antigen for the
negative control zone, 10 µg/mL of HIV 1/2 chimeric antigens (gp 41, gp 36, and O-IDR,
Biolink International) for the HIV zone, and 25 µg/mL of rabbit anti-goat IgG antibody (Life
Technologies) for the positive control zone. For blocking and stabilization, all zones were
treated for 1 hour with StabilCoat Immunoassay Stabilizer (Surmodics, Inc.). Whole blood
samples in EDTA tubes were obtained from Columbia University Medical Center (CUMC)
through an IRB approved protocol. To run the assay, an initial wash of 2 µL of 0.05% Tween-
20 in PBS was drawn through the cassette. The blood sample was gently mixed with dried
lysis agent in a microcentrifuge tube, and 2 µL of lysed blood sample was drawn through
the microfluidic cassette. For hemoglobin measurement, an initial intensity reading (I0(Hb))
is taken during the Tween-20 wash, and another intensity reading (I(Hb)) while the blood
flowed through the cassette. Once the whole blood sample has flown through, pre-loaded
polyethylene tubing (inner diameter: 0.86 mm, Zeus) is connected to the inlet to deliver the
remainder of the reagents, a method previously demonstrated [15, 47]: 14.5 µL gold-labeled
anti-IgM (0.27 µg/mL) and anti-IgG (0.53 µg/mL) antibodies (OPKO Diagnostics) in 3%-
BSA-0.2%Tween-20 in PBS, two 2 µL 0.05%Tween-PBS washes, four 2 µL water washes,
each separated by air spaces (Figure 3.5). This set-up performs the immunoassay described
in Section 2.1.2, and essentially replicates the pre-loaded reagent cassette. In the presence
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of disease-specific antibodies, gold-labeled secondary antibodies bind to the zone surface.
Subsequently, silver nitrate and reducing agents (OPKO Diagnostics) are drawn through the
cassette, and silver ions reduce on gold nanoparticles attached to the surface. An initial in-
tensity reading (I0(HIV )) was taken immediately after silver entered the channel, and another
intensity reading (I(HIV )) was taken after 6 minutes of silver development (Figure 3.6). Lysis
Figure 3.6: Optical density of zone over the 15 minute dual-assay. To measure hemoglobin
concentration, photodiode readings are taken in zone 1 while channels are filled with 0.05%
Tween-20 PBS (I0(Hb)) and blood (I(Hb)). To measure optical density of immunoassay zones,
photodiode readings are taken in zones 2-5 when silver first enters the channel (I0(HIV )) and
6 minutes afterwards (I(HIV )).
buffer optimization experiments were read on a bench-top analyzer (OPKO Diagnostics);
the dual hemoglobin measurement and HIV immunoassay was performed on the dongle.
3.3 Results
We leveraged the precise optics of our smartphone dongle and modified it to quanti-
tatively measure hemoglobin concentration. The device has five optical zones, aligned with
the five test zones on the injection molded microfluidic chip, although only four were used for
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the dual hemoglobin measurement and HIV immunoassay. The first test zone was dedicated
to hemoglobin measurement and the second, third, and fourth test zones were dedicated
to the HIV immunoassay (negative control, HIV-specific zone, and positive control) (Figure
3.4B). In this work, the first optical zone was dedicated to hemoglobin measurement: a green
LED (530 nm) is aligned directly atop the test zone with a 1 mm pinhole and green-sensitive
photodiode (570 nm) aligned directly below the test zone (Figure 3.5). When whole blood
filled the test zone, hemoglobin absorbed the 530 nm light, proportionally reducing the light
sensed by the photodiode. Samples with higher hemoglobin concentration showed higher ab-
sorbance, while samples with lower hemoglobin concentration showed correspondingly lower
absorbance.
3.3.1 Correlation between OD and hemoglobin concentration
To obtain a correlation between optical density and hemoglobin concentration, we
tested a range of whole blood hemoglobin concentrations (0.0 - 21.2 g/dL). The dongle took
two photodiode intensity readings: one while channels were filled with a 0.05% Tween-20
PBS wash (I0(Hb)) and another while channels were filled with lysed blood (I(Hb)), values
were read out to a computer. Reagents flowed through channels with syringe-generated
negative pressure, and readings were taken under constant flow. With this dongle, power-
free fluid flow and a smartphone interface have previously been demonstrated(Chapter 2);
we focused on testing the optical capabilities of the dongle for hemoglobin measurement. We
found optical densities obtained with our device showed a strong linear correlation (R2 =
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0.99) when compared with Hemocue readings (Figure 3.7).There was an average coefficient
of variance of 2% between technical replicates.
Figure 3.7: Calibration curve showing correlation between our optical density measure-
ments with standard Hemocue readings. Data are averages ± SD (n = 3).
3.3.2 Selecting a lysis buffer
Lysis of red blood cells is important for reproducible measurements of hemoglobin
concentration in the microfluidic channel by creating a homogenous hemoglobin solution for
accurate correlation with absorbance readings. The conditions to completely lyse red blood
cells were: sodium deoxycholate (5% w/v, in PBS), CHAPS (48mM, in PBS), Triton X-
100 (10mM, in PBS), and Triton X-100 (10mM, in H2O). Sodium deoxycholate in H2O and
CHAPS in H2O did not fully lyse blood. Blood mixed with dried PBS or mixing alone also
did not cause lysis.
We next wanted to ensure that the addition of a lysis agent (used for hemoglobin
measurement) would not affect the diagnostic performance of the immunoassay. Our im-
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munoassay utilizes gold-labeled secondary antibodies with silver amplification, so presence
of disease specific antibodies creates an optically darkened zone that can be detected with
simple optics. To run the assay, reagents were drawn through the microfluidic channels
using syringe-driven negative pressure (-34 kPa) in the following order: wash buffer, lysed
blood sample, gold-labeled secondary antibodies, wash buffers, and silver reagents. The HIV
Figure 3.8: Immunoassay results with various lysis buffers. (A) Comparison of immunoas-
say signal (measured in optical density) of an HIV positive sample in the presence of five
different lysis conditions: no lysis, 48mM CHAPS in PBS, 10mM Triton X-100 in H2O,
10mM Triton X-100 in PBS, and 5% w/v sodium deoxycholate in PBS. Data are averages
± SD (n = 3). (B) Comparison of diagnostic accuracy using 11 whole blood samples from
Columbia University Medical Center (5 HIV positive, 6 HIV negative) under three lysis
conditions: no lysis buffer, 48mM CHAPS in PBS, and 10mM Triton X-100 in water.
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immunoassay was performed on whole blood mixed with sodium deoxycholate (5% w/v, in
PBS), CHAPS (48mM, in PBS), Triton X-100 (10mM, in PBS), and Triton X-100 (10mM,
in H2O) and performed as described previously [13, 15]. In an initial screening of the four
lysis conditions with an HIV positive sample, sodium deoxycholate significantly decreased
the immunoassay signal, while CHAPS and Triton X-100 showed no significant difference
(Figure 3.8A). Further, sodium deoxycholate increased the time to flow the blood sample
through the channel by several fold, which increased the overall assay time and could lead to
clogging of the channels. On the other hand, CHAPS and Triton X-100 mixed with whole
blood had approximately the same flow time as blood without lysis agent.
Next, we tested 11 samples under three different lysis conditions (no lysis buffer,
CHAPS, or Triton X-100) to see if clear separation between optical density of HIV positive
and negative samples was preserved amongst a larger sample of patients. With both lysis
buffers, some positive samples had decreased OD, however, the negative samples also had a
much lower OD, preserving the separation. A cutoff point was selected for each data set that
provided maximum sensitivity and specificity. Without lysis buffer, the immunoassay showed
100% (95% CI: 48-100%) sensitivity and 100% (95% CI: 54-100%) specificity. Blood lysed
with CHAPS (40mM, PBS) showed 100% (95% CI: 48-100%) sensitivity and 100% (95% CI:
54-100%) specificity, and blood lysed with Triton X-100 (10mM, H2O) showed 80% (95%
CI: 28-99%) sensitivity and 100% (95% CI: 54-100%) specificity (Figure 3.8B). Data are
presented as ratios of signal to cutoff with a horizontal dotted line at y = 1, representing the
cutoff. We selected CHAPS (48mM, in PBS) as our lysis buffer as it preserved diagnostic
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accuracy, even increasing the signal-to-cutoff ratio in several positive samples. The positive
control signal was decreased with CHAPS, however, it still provided a strong enough signal
to indicate that the immunoassay had been executed properly.
3.3.3 Validation of dual-assay on clinical samples from Columbia
University Medical Center
The dongle was then validated for the hemoglobin measurement and HIV dual-assay
on 38 clinical samples from CUMC. For hemoglobin measurements, the dongle took two
photodiode readings (read out to a computer) while 0.05% Tween-20 PBS filled the chan-
nel (I0(Hb)) and while the whole blood sample filled the channel (I(Hb)). Next, gold-labeled
secondary antibodies, washes, and silver amplification reagents flowed through the chan-
nel. The dongle took photodiode readings as soon as silver reagents filled the channel
(I0(HIV )) and 6 minutes after (I(HIV )) (Figure 3.7). Reagents flowed through the channel
with syringe-generated negative pressure, and all readings were again taken under constant
flow. Estimated hemoglobin measurements were calculated based on the line of best fit from
the calibration curve. Samples 14-38 were performed on a different device, and estimated
hemoglobin was calculated with a device specific calibration curve (Figure 3.9).
Estimated hemoglobin concentration showed strong agreement when compared with
Hemocue readings (Figure 3.10A). Estimated hemoglobin showed an average bias of 0.07
g/dL and 95% limits of agreement between -1.08 to 1.22 g/dL (Figure 3.10B). The average
difference between methods was 2.8 ± 2.4% of Hemocue hemoglobin measurement. The
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Figure 3.9: Calibration curve for a second device showing correlation between optical
density measurements compared with Hemocue readings. Data are averages ± SD (n = 3).
majority of the samples (34 of 38) differ less than 7% between our test and the Hemocue
measurement, consistent with the criteria of acceptability by CLIA 88 requirements (in fu-
ture testing, this consistency would have to be further validated with a lab-based hematology
analyzer). While complete blood count (CBC) results were available for most samples, the
reported hemoglobin value on CBC was often several g/dL lower than the result given by
Hemocue, likely because plasma had been taken from the sample for other testing. The av-
erage of two readings from a Hemocue Hb 201+ was taken for comparison. Reference results
for HIV status were determined on Abbott ARCHITECT i2000sr using the 4th generation
HIV antibody combination assay at CUMC. The HIV immunoassay showed sensitivity of
95% (95% CI: 74-100%) and specificity of 95% (95% CI: 74-100), comparable to our pre-
vious results (Figure 3.10C). The receiver operating characteristic curve graphs sensitivity
and specificity for all possible cutoff points, showing area under curve (AUC) of 0.99 (Figure
3.10D).
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3.4 Discussion and Conclusion
This work demonstrates a proof of concept for a novel device that combines hemoglobin
measurement and HIV immunoassay. Traditionally, multiplex tests have been restricted to
tests of similar assay types, even though the clinical scenario may call for a variety of assay
types. In the case of antenatal care, screening for both HIV and anemia are important, and
their integration into a single device can streamline workflow for a healthcare worker. To
perform multiple types of tests in one platform, the chemistry of the different tests (including
lysis, signal amplification, and washings) must be mutually compatible, and different con-
cepts for signal readouts must be integrated within the same hardware instrumentation. For
example, for lateral flow tests, it is traditionally difficult to integrate more than one or two
measurements even within the same type of assay because of limitations in reagent handling
[48], although some manually operated solutions have been proposed [49]. In our expanded
smartphone dongle, photodiode readings for hemoglobin measurement occur simultaneously
with steps in the immunoassay, adding no additional time to the assay. Moreover, LED
power and photodiode readings would consume only 8.5 mW over an additional 1.6 s, which
is a negligible addition to the 0.22 mWh test. The hemoglobin test added no extra cost to
the hardware and negligible added per-test cost for CHAPS, while replacing a diagnostic
test that typically costs $1 per test run with an $800 reader [41].
Although our optical setup has previously demonstrated semi-quantitative capability
with HIV antibody titers [16], this work is the first demonstration of the devices precise optics
for a fully-quantitative assay with clinical diagnostic value. With modifications in reagent
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sequence and optical detection wavelengths, our device could potentially be applied to other
applications with a colorimetric readout, including measurements of glucose concentration,
total protein, and serum iron levels. If it can be demonstrated that the assay in one zone
does not interfere with those of other zones, this smartphone dongle could offer a broadened
range of diagnostic panels, combining immunoassays and colorimetric assays, to the point
of care. Overall, different cassettes pre-programmed for different diagnostic panels could be
offered that use the same low-cost hardware.
More immediately, for antenatal care, this diagnostic test could readily be expanded
to incorporate a syphilis detection zone, as previously demonstrated (Figure 4.5), for an
integrated panel of the most common screening tests for antenatal care in developing coun-
tries: HIV, syphilis, and anemia [33]. Currently, we are only using four immunoassay zones
(hemoglobin, HIV, negative control, positive control), though there are five available. Fur-
ther large-scale testing will be needed to validate sensitivity and specificity. Washes and
surface chemistry can be modified to enhance diagnostic accuracy. To enhance ease of use
for the end user, CHAPS can be lyophilized within the sample collection system (as we
previously performed for other reagents(Figure 2.5)), allowing for red blood cell lysis and
hemoglobin measurement without any additional steps to the user. The envisioned system
would utilize pre-loaded reagents and a one-push vacuum to generate microfluidic flow (Fig-
ure 2.7). Further, the smartphone interface allows for data collection over many patients,
and also offers the potential for connectivity to centralized EMRs, an important feature for
maturing healthcare systems. Overall, this work demonstrates the capacity for a clinically
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relevant diagnostic panel in a user-friendly and field-ready format.
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Figure 3.10: Thirty-eight samples from Columbia University Medical Center were tested
simultaneously for hemoglobin concentration and HIV-specific antibodies. (A) Plot compar-
ing Hemocue readings with hemoglobin calculated based on optical density readings, dotted
line is the line of equality. (B) Bland-Altman plot comparing mean of actual and estimated
hemoglobin with difference between actual and estimated hemoglobin concentration. Dotted
lines indicate 95% limits of agreement. (C) Dot plot showing signal-to-cutoff ratios for 19
HIV positive and 19 HIV negative samples. (D) Reciever operating characteristic curve of
results shown in (C).
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Chapter 4
Demonstrating use of a smartphone
accessory at the point of care
4.1 Background
Testing in the field is critical to understand the utility of a device engineered for
a specific setting. Numerous variables that cannot be tested in the laboratory can affect
how well a diagnostic works, including: heat, humidity, usability by intended users, fit into
the health system, and cultural appropriateness, to name a few. In the field, sensitivities
have been reported to be as low as 82% and specificities as low as 85% for the widely
used HIV RDTs [50–52]; 64-96% sensitivity and 97-99% specificity for treponemal syphilis
antibody tests (Determine, SD Bioline, Syphicheck, VisiTect, and Chembio) [53–55]; and
85% sensitivity and 96% specificity for non-treponemal syphilis antibody test (Chembio)
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[55] on whole blood (fingerprick or venipuncture) performed by trained staff. RDTs are
also limited in number of markers in a single test, subjective user interpretation of band
intensities, and lower sensitivity and reproducibility than lab-based tests.
Early diagnosis and treatment of such diseases in pregnant mothers has been shown
to reduce adverse health consequences to both mothers and their children [56]. Treponemal
antibodies appear earlier than non-treponemal antibodies in syphilis infection [57], and have
been used in syphilis rapid diagnostic tests (RDT). For our assay targets, we chose HIV and
treponemal syphilis antibody tests from our previous work, while detecting a third target,
anti-cardiolipin antibody, as a non-treponemal syphilis marker. In addition, we added IgM as
a secondary antibody for early syphilis detection [57]. While p24 antigen detection is included
in current 4th generation HIV rapid diagnostic tests, several large scale studies have shown
that it is ineffective at detecting acute infection [58]. The Centers for Disease Control and
Prevention (CDC) recommends a non-treponemal (e.g. rapid plasma reagin, RPR) test on
all anti-treponemal enzyme immunoassay reactive specimens (Centers for Disease Control
and Prevention 2010). However, a triplex test with HIV, treponemal syphilis, and non-
treponemal syphilis results is not currently available commercially and clinically. As such,
our device is advantageous in that it would help to characterize the infection as active or
inactive [because treponmemal syphilis antibody level remains high for life [57], thus saving
diagnostic time and simplifying treatment workflow [57, 59, 60].
Here, we demonstrate the field performance of three point-of-care ELISA-quality tests
run simultaneously on a smartphone dongle under the following conditions: i) the tests were
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run by health care workers (HCWs); ii) the tests were run on fingerprick whole blood collected
fresh from intended end-users (patients); iii) and the tests were run in a blinded manner
where the reference-lab results were unknown until testing of all subjects had concluded. In
a 15-minute assay, the dongle provided accurate diagnostic results on triplexed markers for
HIV and syphilis, suggesting that lab-quality diagnostic services could be made accessible
to any population with smartphones.
4.2 Methods
4.2.1 Surface modification of microfluidic cassettes
All cassettes were prepared at Columbia University before transporting to Rwanda.
Like many ELISA assays using plastic 96-well plates, we used direct physisorption of antigens
onto our plastic microfluidic cassettes (OPKO Diagnostics) [15]. We selected recombinant
multi-epitope chimeric antigens (gp41, gp36, and O-IDR) for an HIV 1/2 (Biolink Interna-
tional) marker, a 17-kDa recombinant outer membrane protein TpN17 (Lee Labs) [16, 56] for
a treponemal syphilis marker, synthetic cardiolipin prepared from plant source [61] provided
by CDC for a non-treponemal syphilis marker, and rabbit anti-goat IgG (Life Technologies)
for a positive control. For an internal negative control (provide background signal), the sur-
face was not functionalized with any protein, but treated with blocking agent. The spotting
conditions were as follows: 36 µl each of 2 µg/ml of HIV chimeric antigens, 15 µg/ml of
TpN17, and 10 µg/ml of anti-goat IgG in carbonate-bicarbonate buffer solution (pH 9.6)
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were spotted on the detection zones using a robotic arm as an automated fluid dispenser.
Because of the small size of the cardiolipin molecule, different surface chemistries were used
for cardiolipin functionalization on plastic surface. Cardiolipin was covalently attached to
the plastic surface using EDC-Sulfo-NHS reaction. We used robot-assisted manufacturing
(adapted from OPKO Diagnostics) for reproducible and high-throughput cassette prepara-
tion.
4.2.1.1 Blocking and stabilizing agents
To preserve the conformation and reactivity of the adsorbed antigens, we analyzed
the performance of three blocking/stabilizing agents: casein (Thermo Scientific), SeaBlock
(Thermo Scientific) and StabilCoat Immunoassay Stabilizer (Surmodics Inc.). In evaluating
the blocking agents, the optimization goals for each detection zone were as follows: (1)
minimize noise on the negative control zone; (2) minimize non-specific binding on target
zones for tests with disease-negative samples; (3) maintain optimal conditions for antibody
binding on target zones for tests with disease positive samples, and (4) maintain high positive
control signals for all tests. Cassettes were functionalized with the various protein markers
as described above. Fluid was dispensed by manual pipetting onto cassette surfaces. Each
detection zone was spotted with 36 µl of blocking agent and incubated for 1 hour at room
temperature in a humid chamber. After incubation, the blocking agent solution was aspirated
and plastic cassettes were placed in a vacuum desiccator for 20-30 minutes. The vacuum-
sealed chamber containing the microfluidic cassettes was then placed in a 30◦C oven for
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4-6 hours of secondary drying. Cassettes were sealed with clear adhesive tape (OPKO
Diagnostics) and stored at 4◦C until use. An HIV/Syphilis co-infected sera sample as well
as a disease negative sera sample both diluted 75x in 1% BSA - 0.05% Tween-20 in PBS
were tested on cassettes prepared with each blocking agent.
4.2.2 Study design
The goal of this study was to develop a power-free lab-on-a-chip device for HIV and
syphilis diagnosis in resource-limited settings. To evaluate dongle performance, the device
was deployed in Rwanda, into the hands of HCWs that did not have ELISA training, for
prospective diagnosis of patients already scheduled to receive HIV and syphilis testing. This
study was approved by Columbia University IRB and Rwanda National Ethics Committee.
In order to guide field evaluation of this study, site selection consideration took place between
the study team, ICAP and the Rwanda Bio-Medical Center (RBC). Three community-level
health centers (HC) in Kigali, Rwanda were selected for this study: 1) Kimironko HC, serving
56,000 people, 2) Biryogo HC, serving 50,000 people, and 3) Gahanga HC, serving 28,000
people.
4.2.2.1 Healthcare workers
HCWs involved in the study were lab technicians at the health centers and selected
based on willingness to participate in the study. The five health care workers that used the
dongle all were female (age 26-47), lab technicians with a range of clinical experience (7-24
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years). Of these, one was also a level 2 nurse (an advanced certificate following three years
of tertiary education), two were level 1 nurses (Bachelor’s degree). All had experience with
HIV rapid tests (using sera/plasma) and fingerprick technique (for malaria, HIV rapid tests
or hemoglobin).
HCWs who agreed to participate in the study were trained by the study team at
beginning of the study at each study site. The training was carried out using a handout
to provide background and basic information of the study and hands-on training on how to
perform the dongle tests using fingerprick whole blood. The training session was approxi-
mately 30 min at each site. On regular basis, more than 50% of patients have to wait for
results without knowing how long it takes while 35% have to wait more than 2.5 hours to
receive their results.
4.2.2.2 Patient enrollment
All patients who were enrolled in PMTCT or VCT programs over a 2-week period, and
who provided consent, participated in this study. Study subjects were primarily recruited
from patients currently enrolled in PMTCT and VCT programs in selected sites by HCWs
using a recruitment script provided by the study team. Patients who showed interest in
the study were referred to the study team (Rwandan study facilitator) for further study
information and receive the consent via third party translator. Patient was enrolled in a
first come, first served basis and his/her participation was completely voluntary and did not
affect the received services at any health facilities. Of the 96 participating patients, average
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age was 31 years old (range: 21-62) with 40 males, 33 non-pregnant females and 23 pregnant
females. Thirty eight were enrolled in PMTCT, 52 in VCT, and 6 in General Consultation
for HIV/STIs (GC). We did not perform power analysis; instead we chose a sample size of
100, which allowed us to focus on incorporating device testing with clinic flow, getting user
feedback, and assessing patient reception, in resource-limited settings.
After consent, patients were subjected to two blood draws by trained HCWs: venipunc-
ture for routine laboratory tests as they originally came to the clinic for, and an additional
fingerprick (less than 5 µl) specifically for the dongle assay testing. Participants were given
a questionnaire regarding their medical history as well as their experience with the don-
gle assay. These questionnaires were administered by a third-party interviewer who was
French/Kinyarwanda/English speaker. Responses to questionnaires were written in English
by the third-party interviewer and returned to the study team for analysis. Participants
were compensated 1000RWF ($1.54 USD) for their time. Disease statuses were blinded to
the Columbia team and HCWs who conducted the test. A flow-diagram of study procedures
is depicted in Figure 4.1.
4.2.2.3 Confirmation testing
HIV testing at each study site was done for all participants using blood plasma.
In accordance with Rwanda’s HIV testing algorithm, Gold Colloidal HIV 1/2 Ab (KHB
Shanghai Kehua Bio-engineering) was used as a screening test, followed by Alere Determine
HIV-1/2 Ag/Ab (Alere) as a confirmatory test, and a Uni-Gold Recombigen HIV 1/2 Ab
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Figure 4.1: Flow diagram outlining study procedures for field trial in Kigali, Rwanda.
(Trinity Biotech) was performed if results of first two rapid tests were discordant. An aliquot
of plasma ( 0.5 ml) from each specimen was transferred to Rwanda National Reference Lab
(NRL) for a confirmation test using Vironostika HIV Uni-Form II Ag/Ab (bioMérieux). All
tests were performed in a blinded manner by local lab technicians. Syphilis testing at each
study site was done for only for PMTCT participants with RPR test (Spinreact). Aliquots
of each plasma specimen at NRL were tested using TPHA (Spinreact) and RPR tests as
reference tests for treponemal-syphilis and non-treponemal syphilis, respectively.
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4.2.2.4 Confidentiality and privacy protections
All data collected during the interviews were de-identified and labeled with a sequen-
tial unique study ID number by the interviewer. Names or other individually identifiable
information were not recorded on any data collection document. Written consent forms,
containing subject name and signature, were the only documents with patient identifiers,
with no linkage to data collected. Study staff were trained on Good Clinical and Labora-
tory Practices (GCLP) and signed a confidentiality agreement prior to commencement of
study. Individual interviews were held in a private space within the health facility to protect
subjects’ confidentiality.
4.2.3 Statistics
Averages, standard deviations, linear fit, and two-sided Student’s t-tests (α = 0.05)
were calculated with Microsoft Excel. Student’s t-test was chosen to compare two small sets
of quantitative data when data in each sample set were related. Vertical scatter plots, sen-
sitivity, specificity, 95% confidence intervals, ROC curves, and McNemar’s test were created
in GraphPad Prism.
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4.3 Results
4.3.1 Microfluidic assay
We built on our previous work for HIV/syphilis detection [15] in five major ways.
First, we expanded the detection zones in the disposable microfluidic cassette from four to
five zones, for detecting HIV, treponemal syphilis, and non-treponemal syphilis antibodies
simultaneously with internal negative and positive controls. Second, gold-labeled IgM an-
tibodies were added to the assay (Figure 4.2A). Anti-cardiolipin antibodies are commonly
found in IgM antibodies, and therefore, the addition of gold-labeled IgM offers enhanced
sensitivity of non-treponemal syphilis.
Figure 4.2: (A) Comparison of signal measurements obtained by additional of gold-labeled
anti-hIgM to gold-labeled anti-hIgG and gold-labeled anti-hIgG alone as detection antibodies
for negative, weak positive non-treponemal syphilis (RPR titer 1:2), and strong positive
non-treponemal syphilis (RPR titer 1:32) plasma samples. Data are averages ±1 SD (n=4
for anti-hIgG and n=3 for anti-hIgG:anti-hIgM) (B) Comparison of signal from gold-labeled
anti-hIgG/anti-hIgM antibodies lyophilized in a plastic antibody holder and freshly prepared
in solution. Detection zones were functionalized with human IgG, human IgM and rabbit
anti-goat antibodies. Data are averages ±1 SD (n=3). n.s. not significant, Students t-test.
Third, to improve long term stability in shipping and storage, we lyophilized gold-
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conjugated secondary antibodies inside the antibody holder, along with a stabilizer and
anticoagulant, and packed the holder in an individual moisture barrier bag prior shipping
them to Rwanda. Lyophilized antibodies demonstrated comparable performance to gold-
conjugated antibodies freshly diluted in buffer (Figure 4.2B).
Fourth, to mimic field testing conditions, we prepared the test cassettes ahead of
time at Columbia University before transporting them to Rwanda. By using stabilizing
agent (StabilCoat) during physisorption of capture proteins, the protein retained its original
function over 3 weeks at 60◦C (equivalent to roughly 28 weeks at 25◦C according to Arrhenius-
like approximations [62]). This stabilizer was also found to be effective. Fifth, the wash
buffers and silver reagents were pre-loaded on the reagent cassette each day prior to testing.
In the future, robot-assisted loading of reagent cassettes will be implemented, as reagents
are known to be stable for over 6 months at room temperature [15]and wash plugs have
been shown to stay separated after airborne shipping [47]. These conditions replicated real
shipping and transportation conditions, minimized user steps, and increased field-readiness
to enable a ”plug-and-play” operation for the user.
4.3.2 Field testing with target users
Five HCWs tested fresh fingerprick whole blood from 96 patients, whose disease sta-
tuses were unknown until the reference lab results were un-blinded at the end of the study.
At three health centers in Kigali, Rwanda, HCWs recruited patient volunteers enrolled in
preventing mother-to-child transmission (PMTCT) and voluntary counselling and testing
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Figure 4.3: Stability of functionalized protein on microfluidic cassette. Cassettes were
prepared using StabilCoat Immunoassay Stabilizer (Surmodics). Microfluidic surfaces were
stored for 21 days at 60 ◦C, after which signals on HIV 1/2, treponemal syphilis, and car-
diolipin zones were measured with stored plasma samples. Data are averages (n=2), with
individual data shown as dots. n.s., not significant, two-tailed Students t-test.
(VCT) programs for the study, with our research team providing further information about
the study to participants as needed. Consent forms were translated to Kinyarwanda (the
principal local language), and obtained by a third-party translator fluent in English and
Kinyarwanda. Fingerprick whole blood specimens were collected and coded with a study
ID number with no link to access other health information, to protect patient privacy. In
parallel, venipuncture was performed on the same patients. For reference tests, HIV RDTs
were completed at each site, whereas HIV ELISA, syphilis Treponema pallidum hemagluti-
nation (TPHA), and syphilis RPR reference tests were performed at the Rwanda National
Reference Laboratory using plasma.
4.3.2.1 Device operation
Each day prior to testing at the clinic site, two 2-µl PBS-0.05% Tween-20 and four
2-µl water washes as well as 60 µl each of silver nitrate (Silver A) and silver reducing agent
(Silver B) were loaded to the reagent cassette manually by pipetting and sealed using an
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Figure 4.4: Smartphone dongle at a clinic in Kigali, Rwanda
adhesive tape (OPKO Diagnostics) to mimic pre-packaged reagents. The antibody holder
was pre-filled with 9 µl of 3% BSA-0.05% Tween-PBS just prior to testing.
The dongle app presented a user-friendly interface to aid the user through each test,
step-by-step pictorial directions, built-in timers to alert the user to next steps, and records
of test results for later review. Given the simplicity of running the test, training of HCWs
(lab technicians with no experience in ELISAs) took approximately 30 minutes.
To perform the test, the user mixed 1 µl of whole-blood sample with 9 µl of 1% BSA
- 0.05% Tween-20 in PBS, placed 2 µl of the mixed sample into the cassette, attached the
antibody holder into the cassette, inserted the cassette into the dongle, pressed the bulb fully
to initiate vacuum, and pressed ”Start assay” on the app to start Phase 1 of the test. After 5
minutes, all reagents downstream of the venting port (gold-labeled antibodies, and washes)
will have passed through the chip. For silver development, or Phase 2, the user was then
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prompted to slide the toggle to close a venting port, to initiate flow and mixing of silver A and
B. The two silver reagents were stable separately and thus stored separately on the reagent
cassette; the venting port design allowed mixing of the silver reagents immediately prior to
use, minimizing silver auto-catalysis. To prevent exposure of chemicals to the user, sample
and reagents were contained in a membrane filter within the cassette, and the antibody
holder was securely connected to the cassette. OD readings were taken before and after
silver development, and at the end of the assay (15 min) results for all markers are available
and clearly displayed on the app interface.
Each patient venipuncture whole blood was tested by the Columbia team using the
in parallel with the fingerprick blood testing. An aliquot of venipuncture whole blood ( 50
µl) was made from each whole blood collected. Venipuncture whole blood was processed in
the same manner as the fingerprick blood.
4.3.2.2 Dongle results compared to gold standard
The test results for detection of each marker are compared with the gold standards
of lab-based HIV ELISA, TPHA, and RPR, and are presented in terms of signal-to-cutoff of
each target relative to its reference test displayed as vertical scatter plots and ROC curves.
Cut-off values to determine if a sample was positive or negative for each marker were selected
by using receiver-operating characteristic (ROC) curves. Although a final product will offer
preset cut-off values, in this development work, we identified cut-off values retrospective
to data collection that maximize sensitivity (minimize false-negatives) because our test is
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targeted towards screening applications. Cut-off values for internal negative and positive
controls were also applied to verify validity of test results; no tests were excluded based on
these criteria. An indeterminate range (e.g. if OD is within 10-20% of cut-off) [63] can be
implemented for future tests to indicate the need to rerun the test.
The detection of HIV antibodies had a sensitivity of 100% (95% CI: 59-100%) and
specificity of 87% (95% CI: 78-93%). Sensitivity for detection of treponemal antibodies was
92% (95% CI: 64-100%) with specificity of 92% (95% CI: 83-97%). Sensitivity for detection
of anti-cardiolipin antibodies was 100% (95% CI: 48-100%) with specificity of 79% (95% CI:
69-87%). ROC curve shows AUC of 0.96 for HIV, 0.90 for treponemal syphilis, and 0.92 for
non-treponemal syphilis (Figure 4.5). Specifically, there was one false-negative result for the
Figure 4.5: Testing of dongle using clinical fingerprick whole-blood specimens in the field
run by healthcare workers. (Left) Vertical scatter plot of the dongle device signal-to-cutoff
ratios for HIV, treponemal syphilis, and non-treponemal syphilis positive (Pos) and negative
(Neg) samples using fingerprick whole blood compared to gold standard tests (HIV ELISA,
TPHA, and RPR). (Right) A receiver operating characteristic (ROC) curve for each disease
marker.
treponemal syphilis test, and 12, 7, and 19 false-positive results for HIV, treponemal syphilis
and non-treponemal syphilis, respectively. On venipuncture whole blood, the dongle yielded
a sensitivity and specificity of 100% (95% CI: 59-100), 91% (95% CI:83-96) for HIV, 77%
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(95% CI: 46-95), 89% (95% CI: 80-95) for treponemal syphilis, and 80% (95% CI: 28-99), 82%
(95% CI: 73-90) for non-treponemal syphilis (Figure 4.6). There is no statistical difference
of dongle assay performance on fingerprick and venous whole blood with p-values of 0.45,
1.0, and 0.33 for HIV, treponemal syphilis, and non-treponemal syphilis, respectively using
McNemar’s test.
Figure 4.6: Testing of dongle using clinical venipuncture whole-blood specimens in the
field run by the study team. (Left) Vertical scatter plot of the dongle device signal-to-cutoff
ratios for HIV, treponemal syphilis, and non-treponemal syphilis positive (Pos) and negative
(Neg) samples using venipuncture whole blood compared to gold standard tests (HIV ELISA,
TPHA, and RPR). (Right) A receiver operating characteristic (ROC) curve for each disease
marker.
4.3.2.3 Patient survey
To assess user feedback, a third-party interviewer fluent in English and Kinyarwanda
conducted the surveys to reduce any biases from the study team. The questions posed to the
participants focused on dongle/fingerprick preference versus traditional venipuncture (and
why), desired test time, and whether the dongle would be recommended (and why) (Figure
4.7). A vast majority of patients (97%) would recommend the dongle to others because of
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Figure 4.7: Survey results from patients regarding their experience with the dongle
the fast turnaround time (57%), potential to offer results for multiple diseases (44%), and
simplicity of procedure (29%). Fingerprick blood collection was preferred to conventional
venipuncture by 95% of patients because: it is less painful (98%), takes shorter time (60%),
the HCW had trouble with the needle collection (55%), the patient is scared of a needle
(43%), and a fingerprick takes less volume of blood (42%). However, 2% of patients preferred
venipuncture because they trust the result more with venous blood. HCWs appreciated the
lack of user interpretation to read the result or external power to operate, and also noted
in surveys that the dongle could be useful in low-volume testing sites (e.g. VCT or mobile
visit) or serve as a backup test for high-volume patient clinics in case of power outage, which
we experienced during testing.
4.4 Discussion and Conclusion
This dongle presents new capabilities for users ranging from health care providers to
consumers. For HCWs, management of infectious diseases could be improved with access
to multiplexed test at the point of care (POC). For example, for syphilis, health-impact
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modeling has shown a test with only 70-80% sensitivity and specificity, but that can be
performed truly at the POC, can reduce deaths by 10-fold over a hypothetically perfectly
accurate lab-based test [5] by increasing detection of infections. For large-scale screening,
high sensitivity (with few false negatives) is most important, as is achieved by the dongle. For
HIV, scaling up HIV testing at the community level with immediate antiretroviral therapy
could nearly stop HIV transmission and approach elimination [64].
Testing in the field allowed us to gain valuable insights on usage of our device in
its intended setting. In the testing procedure, HCW would initiate phase 1 (sample, gold
seconary antibodies, and washes), wait 5 minutes, slide the toggle to initiate phase 2 (silver
amplification), and have to wait another 6 minutes for phase 2 before results were available.
Healthcare workers often multitasked during the testing and commented that it would be
very helpful to eliminate the middle step of sliding the toggle to initiate silver amplification.
Further, we learned much about the robustness of our device with heavy usage. We found
that the audiojack ,as designed was noisy and prone to breakage, needing intermittent repair.
The rubber o-ring connecting the vacuum to the outlet wore down after repeated usage, and
needed replacement about once a week. Similarly, the rubber on the toggle to seal the silver
port also wore down over time. Each these insights would not be possible without repetitive
and high-volume use by healthcare workers.
Importantly, healthcare workers commented that our system is designed for testing
one sample at a time, and could be potentially useful as a back-up system in their clinics
(as power is sometimes unreliable), or lower-throughput settings (mobile clinics, lower-level
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clinics). Gaining a first-hand view of clinic staff responsibilities, flow, throughput, allow us
to better understand where our testing system would provide the most benefit.
The dual test for syphilis holds clinical value for HCWs. The current procedure
in many developing countries calls for a single lab-based qualitative RPR test for syphilis,
such that all patients with positive non-treponemal results are recommended for treatment.
Because this procedure can lead to overtreatment, given the intrinsic lower specificity of non-
treponemal assays [59, 60], a number of countries are adopting treponemal-specific RDTs
[65]. However, blanket treatment of patients testing positive with a treponemal-specific RDT
can lead to overtreatment and penicillin resistance, because treponemal antibodies remain
even after infection has cleared. A dual non-treponemal and treponemal syphilis test would
empower HCWs to follow guidelines [59, 60] that recommend treatment under two scenarios:
if both tests are positive, or if treponemal-specific results are positive and the patient either
had no previous infection or exhibits signs of new infection. Differentiation between active
and past infection is particularly valuable in endemic areas, including Rwanda [66]. In
addition, compared to syndromic management [57], POC syphilis tests also help HCWs
avoid overtreatment and improve cost-effectiveness; among our subject group, 13 patients
exhibited positive TPHA results, although only 4 exhibited positive RPR results, and would
all be treated under guidelines with rapid treponemal-specific tests.
It is challenging to use RDTs to detect multiple markers. The dongle is versatile
in that it can detect selectively IgM and/or IgG antibodies on multiple markers. This
capability supports early detection of syphilis, as anti-treponemal IgM antibodies appear
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earlier than anti-treponemal IgG by two weeks [57]. Addition of a non-treponemal test
and detection of IgM, performed alongside HIV, moves another step towards a complete
POC multiplex antenatal-care panel. Performing three individual commercially-available
tests can cost up to $8.50 USD [$0.80-5.00 for HIV RDT [67], $1.00-3.00 for treponemal
RDT [60], and $0.50 for RPR [68]]. By comparison, material and reagents cost per test
for our triplex test is $1.44 USD, leaving room for a substantially lower anticipated market
price. In addition, compared to RDTs, the dongle offers automation of assay, objective
readout of signal, and quantitation, although it requires more instrumentation than RDTs.
RDTs present challenges for untrained users to execute precise liquid handling and metering,
particularly in multi-step tests. Our system contains precise injection-molded cassettes, pre-
loaded reagents, optimized optics, and exact alignment that can reduce user variability.
Add-on optical readers are becoming available for RDTs, but still present challenges to the
user (for example, in positioning and illumination accuracy) as RDTs are originally designed
to be single-step stand-alone tests [69].
Two practical challenges to deploying POC diagnostic devices is specimen collection
and infrastructure of facilities. This dongle test required one fingerprick, or 2 /mul of whole
blood for all three tests (avoiding multiple fingerpricks, a point appreciated by the patients in
the survey), where HIV and syphilis RDTs require anywhere from 5 to 60 /mul each. Another
challenge to blood analysis in resource-poor settings is power outages, which is obviated with
our audio jack-powered dongle. We show that when so little power is needed for diagnostics,
the audio jack connection can power and record an entire laboratory-level immunoassay with
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amplification and washing reagents. Although, the audio jack connection has been used for
data communication in devices, including for heart rate monitoring (Nirjon, Dickerson et
al. 2012), measuring exhaled carbon monoxide in smokers [70], and electrochemical sensing
[26], it has been less adapted for powering health diagnostics devices, typically due to large
energy consumption.
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Chapter 5
Expanding HIV diagnosis outside the
clinic with a smartphone accessory
5.1 Background
In the previous chapter, we demonstrated the performance of a smartphone accessory
for diagnosis of HIV and syphilis in the hands of healthcare workers with only 30 minutes of
training on the device. This expanded the accessibility of the ELISA assay beyond central-
ized laboratories and into health centers (which typically only have rudimentary laboratory
equipment). In this chapter, we seek to further expand the accessibility of our diagnostic
to self-testing, having the patient test themselves. Self-testing has ability to empower a
person to take ownership of his or her own health. The increasing availability of diagnostic
information to non-healthcare professionals, presents fundamental questions on how diag-
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nostic information is to be handled to maximize patient privacy and autonomy while also
maximizing a patients health benefits. When the pregnancy test was first commercialized
in 1977, there was fear that women would be less likely to connect to the healthcare system
in a timely manner, if they could perform tests at home [71]. However, the pregnancy tests
enabled to obtain highly personal and sensitive information in private [72], and actually
promoted earlier connection into the healthcare system [71].
Similarly, with the recent FDA approval of OraQuick HIV home-test kit, there were
questions on how people would react to results without proper counseling or if a negative
test would promote more risky behavior. However, studies have demonstrated certain high-
risk populations to embrace self and partner testing [73], and other studies are ongoing
to understand further implications of self-testing. In less developed countries, the idea of
HIV self-testing has been explored at a policy level, discussing with government, health
professionals, and donors. Most agree with the potential of diagnosing previously unreachable
populations, however, they are apprehensive about the lack of counseling, direct linkage to
care, quality assurance of test results, as well as potential for partner violence [74, 75]. Few
studies outside the US/Europe have examined the users perspective, preferences for testing,
and likely actions surrounding testing.
Over the past decade, smartphones have become nearly ubiquitous in the developed
world, and developing countries are quickly following [19]. Smartphone-enabled diagnostics
have the potential to provide disease-based education, minor counseling [76], and linkage to
care. However, with digitally generated data, new concerns around privacy emerge, and new
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questions around patient privacy and safety must be answered.
We have developed a smartphone accessory that can perform a laboratory quality
immunoassay in just 15 minutes. After a short 30 minute training, Rwandan healthcare
workers were able to operate the device, achieving diagnostic accuracy comparable to other
rapid diagnostic tests run in the field [13]. Because our systems steps are simple and in-
terpretation of results require no training, our device is particularly well-suited to expand
diagnostic testing to completely untrained users. We seek to 1) examine the diagnostic ac-
curacy of our device in the hands of untrained users, 2) understand patient choices around
privacy of sensitive health information, and 3) study how our device can influence patient
choices in seeking care.
5.2 Methods
5.2.1 Device manufacture
Custom-printed circuit boards were designed in Eagle CAD and printed from Penta-
logix. LEDs and photodiodes were precisely aligned with the cassette slot so that testing
zones aligned without manual effort. One-mm pinholes made of 1-mm thick black Delrin
(McMaster-Carr) were aligned above each photodiode to prevent stray light. The dongle
casing was designed in SolidWorks and printed in-house (Objet 24 3D-Printer, Stratasys).
Vacuum chamber was created with a one-way umbrella valve (Minivalve), a rubber bulb from
a 60-mL syringe, and a conical spring (Century Spring Corp) inside to aid re-expansion. Sil-
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icone rubber o-rings and sheets (McMaster-Carr) were used to connect to outlet and seal the
venting port.
5.2.2 Subject selection and study design
Our study was conducted at the Kimironko Health Center in Kigali, Rwanda. Partic-
ipants were recruited from preventing mother to child transmission clinic (PMTCT), volun-
tary testing and counseling clinics (VCT), and CD4 clinic for HIV positive persons. Eligibility
criteria were enrollment in one of these clinics (which test for HIV and syphilis), age 21 - 65,
ability to read, and willingness to perform a self-test. Patients were informed of the study
through clinic informational sessions and clinic staff, and directed to a third-party interviewer
fluent in English, French, and Kinyarwanda for more information and informed consent. This
protocol was approved by Columbia IRB and Rwanda National Ethics Protocol.
After consent, participants were given a pre-use survey to assess their past medical
history, risk factors, and mobile phone usage. For training, participants were first shown a
short 1-minute video on how to operate the device. Next, subjects were presented with a
smartphone app that contained pictures and directions in Kinyarwanda on how to operate
the device. participants were given a demo lancet, demo test cassette, and dongle and given
the opportunity to go through the directions once and practice the test steps with feedback
from the study team. After this training, participants were provided alcohol swabs, lancet,
test cassette, dongle, and smartphone with directions to perform testing on their own with
no feedback from the study team. Participants were graded on a rubric of steps performed
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correctly, and no intervention was given to the user unless they were about to perform a step
that was potentially harmful to themselves. Afterwards, participants were given a post-test
interview to assess their reactions to the test. Total testing time for each participant was
about 1 hour; each was compensated 1000 RWF ($1.33 USD). Participants were not given
diagnostic results as part of their study and received diagnostic results through their normal
clinic visit.
Venipuncture blood (EDTA anticoagulant) was taken from each participants as part
of normal clinic testing. After the clinics testing was completed, the study team used the
dongle on venipuncture whole blood. A small aliquot (about 500 uL) of plasma was taken to
the Rwanda National Reference Laboratory for reference testing by HIV ELISA (Vironostika)
and TPHA (Spinreact).
5.3 Results
5.3.1 Redesigning the device for enhanced usability
Based on our observations from our previous field trial, we made a number of im-
provements to our smartphone dongle that enhance the usability of the test in the hands of
the user.
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5.3.1.1 Eliminating assay steps
We streamlined the assay in two major ways. First, we removed the need for blood
dilution. We were able to adapt the HIV zone to accept neat whole blood by altering the
surface concentration of the antigen on the microfluidic zone. We also removed the need
to pre-fill the antibody holder with buffer to aid with resolubilization. Lyophilized gold
secondary antibody resolubilization occurs within the first few buffer washes, with the later
washes acting to remove non specific binding.
5.3.1.2 Initiating silver amplification
While observing users during the previous year’s field testing, we noticed workers
would often multi-task during the waiting periods. After completing sample collection and
initiating flow, workers would perform other tasks while sample and washes flowed over the
test zones, approximately 5 minutes. They would then have to return to slide a toggle to
connect silver reagents to the fluidic circuit and initiates mixing and flow of silver reagents,
and wait another 6 minutes for amplification to complete. To ease workflow, it would be
beneficial to the use to eliminate this manual step in between these two waiting periods.
Further, because the toggle needed to slide back and forth for each run, the silicone rubber
used to seal the port would get worn down easily, needing to be changed every couple of
days.
We incorporated a small solenoid that would close the venting port on the reagent
cassette. When the solenoid is energized, the armature is pushed down, sealing the venting
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port, connecting the silver reagents to the fluidic circuit. By moving the armature in a down-
ward motion, this reduced the abrasion on the silicone rubber that sealed the port, unlike the
previous design. This activation was controlled through the microcontroller, therefore could
be timed with the assay, and therefore eliminating this cumbersome step for the user. The
solenoid was powered with a 3.7 V, 2500 mAh, rechargeable lithium ion polymer battery. It
used about 400 mA, or 1.48 W when run off the 3.7 V battery. With this battery, we can
run approximately 83 full assays from a fully charged battery, which would last a full day at
a mobile clinic.
While this design effectively eliminated a cumbersome user step while maintaining
portability, the solenoid used almost 175 times the power than any other component in the
device, and would have to be activated for about 4.5 minutes. While eliminating this step
was an important improvement, we felt this one manual step was not enough to justify
the addition of a relatively large battery ( 1/3 of the original dongle volume) and limit
the number of assays that could be run off of a single battery charge. Further, in a low-
throughput setting, such as for self-testing or with community health workers, there may
be less multitasking, and eliminating this user step may not be of as much importance. We
designed a manual switch adapted from a commercially available electrical toggle switch.
Inside the switch, when the switch is pushed in the closed direction, a metal lever is pushed
down to connect with an electrical contact below, thus connecting the circuit. We remove
this electrical contact, and placed a pin in its place, with silicone rubber below. When the
switch is pushed, the metal lever pushes down the pin, which seals the venting port. This
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design is repeatable, robust, and reduces abrasion on the silicone rubber. While this step is
manual for the user, it is power-free and has a small form-factor, and does not increase the
overall size of the device.
5.3.1.3 Powering and data communication
On the device, we changed data communication to Bluetooth, leading to faster data
transfer and a more reliable connection. Our implementation of FSK allowed us to have a
maximum data transfer rate of 1 bps, translating to a data transfer time of 90 s for five
16-bit integers. We attempted to increase the baud rate of data transfer, as literature claims
as much high as 300 bps [29], however, a noisy signal did not allow for accurate data trans-
fer. The audiojack connection to the board, as designed, was prone to noise and breakage,
and required repairs approximately once a week during the previous round of field testing.
Further, energy harvesting from the smartphone audio jack can have variable efficiency. Au-
diojacks from different smartphone models can have varying impedances, strongly affecting
the efficiency of power harvesting [29].
We connected a Bluetooth module (Adafruit) to our microcontroller. The microcon-
troller was programmed to ait for a signal from the smartphone, once received the microcon-
troller would proceed to take light intensity readings of each zone, and send the information
back to the smartphone. With this set-up we are able to transfer all five 16-bit integers in
under 1 second. The Bluetooth module uses an average of 4.6 mW, which is higher than the
average 1.5 mW used for FSK, though still incredibly low.
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Without an audiojack connection, we powered the device with a small button cell
battery (CR2032, 3.0 V). With a power consumption of 4.6 mW, a single battery is estimated
to last about 760 assays. The button cell battery allowed for a more stable power supply
leading to more precise optical measurements. When the dongle was powered through the
smartphone audiojack there was a 10.3% CV between replicate readings, whereas powering
with a button cell battery provided a 2.8% CV between replicat readings. Additionally, by
increasing the LED intensity from 150 mcd to 1100 mcd, we were able to further decrease
CV of signals to 0.23% between replicate readings. These changes allowed for a more robust
and reliable readings, particularly between devices.
Figure 5.1: Improving optical reproducibility by using battery power and increasing LED
intensity.
5.3.2 Field trial results
With a more user-friendly robust, field-ready device, we aim to examine the following
endpoints: 1) assay performance in the hands of untrained users, 2) user acceptability of
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data sharing of sensitive information to the cloud, and 3) user acceptability of a diagnosis
through a smartphone interface.
5.3.2.1 Patient demographics
We recruited 66 patients over 2 weeks: 2 were excluded because they did not wish to
fingerprick themselves, 7 were excluded because they could not read, 4 were outside the ages
of 21-65, and 57 patients completed the entire testing procedure (Figure 5.2). The majority of
patients (69%) had a primary school education, while 28% had completed secondary school,
and only one had completed undergrad. Most lived in an urban area (86%). Median travel
time to clinic for all participants was 60 min, ranging from 2 - 180 min. Median annual
income was 60,000 RWF ($80 USD), range 0 to 2,400,000 RWF (0 to $3200) (Figure 5.3).
Figure 5.2: Total participants included in study.
The majority of participants also owned a mobile phone (89%): 78% had basic phones,
19% had internet enabled phones, and 13% had smartphones. Two participants owned two
phones. Phones were primarily used for texting (78%) and calling (94%), though a majority
(72%) used their phone for some other purpose as well (photos, music, watching videos,
games, etc.) (Figure 5.4).
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Figure 5.3: Participant demographics.
5.3.2.2 Participant training
For the first fifteen participants, we provided them with fingerpricking materials (al-
cohol swab, lancet, gauze, bandage), one disposable test (one test cassette, one sample col-
lector), the dongle, and the smartphone. Participants were instructed to follow the picture-
based directions on the screen, and provided minimal additional assistance. If participants
got stuck or confused for a long time, the study team would explain the step and move on,
while noting this assistance in the rubric scoring.
In observing participants in this session, they got an average of 12.4 steps out of 15
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Figure 5.4: Mobile phone usage among participants.
correct. We noticed the following difficulties:
1) Using the smartphone interface. The interface was designed with 1-2 steps per page,
with the text ”Next” in blue at the bottom to proceed to the next page. Most participants
did not have a smartphone, and seemed unfamiliar with the touchscreen interface. Further,
the indication of blue words as an active link was unfamiliar. A few users saw the word
”Next” at the bottom of the page, right above the home button, and pressed the home
button instead.
2) Sample collection. The sample collector was designed by OPKO Diagnostics to
hold a total of 11 muL of fluid (specific to their assay), though in our assay we only require
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2 muL of blood. We drew a line on the sample holder and the app instructed the patient
to fill blood only up to the black line, with a demonstrative picture. We found this was a
complicated step with many levels of instructions: first identify Part A, identify the side
with the orange sticker, then collect blood into the capillary tube only to the black line. We
found many participants were confused at each stage: which piece to pick up, which part of
the sample holder (Part A) collected the blood, and often filled beyond the black line.
3) Connecting the sample holder (Part A) and test cassette (Part B). The sample
holder (Part A) and test cassette (Part B), connect in a perpendicular manner, with the
ends of the capillary tube in Part A inserting into two holes on Part B. However, on the
reagent holder of Part B, there are actually many holes, and the orientation of Part A and
Part B was very difficult to discern from a static picture.
4) Fully inserting the test cassette into the device. When the cassette is fully inserted
into the device, the test zones are repeatably aligned with the LEDs and photodiodes to
assess optical density of each of the zones. Each cassette had a black line indicating how far
the cassette should be inserted. Inserting the cassette took a fair bit of effort, as we wanted
to ensure a tight seal between the cassette outlet and the vacuum pump (connected with a
rubber o-ring). As a result, many participants were still unsure how far to push the cassette.
5) Pushing the bulb to initiate the vacuum. We used a vacuum bulb to initiate vacuum
with the same mechanism as the previous design: when the user pushes down on the bulb, air
exits out the one way valve, and the bulb re-expands to create a relative negative pressure,
driving fluidic flow. With the instructions to push the bulb, sometimes users would not push
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enough, only depressing the bulb halfway, thus not generating enough vacuum to drive fluidic
flow for the full 5 minutes. More often, users would push and hold the bulb, not knowing
how long to hold it, or even if they should release. While the bulb is being depressed, air
also gets pushed through the cassette outlet, back through the test cassette and can push
the blood through the sample collector into the reagent cassette, and sometimes all the way
out the venting port.
To mitigate these issues, we made adjustments to both our app and training proce-
dures. On the first issue, we changed the button to be a prominent bright blue box, and
further clarified the instructions to say ”Press here to continue”. On the remaining issues,
we realized these each were issues that could be engineered differently in the next iteration.
However, while in the field, we wanted to gain a better understanding of the ease of perform-
ing each of these steps. For the next 36 participants, we incorporated an instructional video
as well as a training session where users could do a ”dry run” with the instructions and the
test pieces as well as receive feedback from the study team. This allowed participants to get
familiar with the pieces and the test procedure, particularly understanding the orientation
to connect Part A and Part B, as well as
The training took an average of 11 minutes (range: 5 - 19 minutes). Completing the
test took an average of 20 minutes (range: 13 - 40), compared with the first set of patients
who took an average of 27 minutes (range: 21 - 40). With this second set of participants, we
observed an average of 13.7 steps out of 15 correct compared with 11.3 out of 15 steps correct
from the first set of participants (p ¡ 0.001) (Figure 5.5). Twelve of the 36 participants in
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Figure 5.5: Steps performed correctly for first set of participants (n = 15) and second
set of participants (n = 36). Steps in bold represent those with statistically significant
improvement (p¡0.001) between the first and second sets.
the second set (33%) performed all steps correctly, however only 4 were able to complete
the assay to positive control. Given the low number of fully completed runs, it is difficult
to assess whether the participant generated data is comparable to assay performed by the
study team.
5.4 Discussion
With only a short 11 minute training, we found that participants, majority of whom
only had a primary school education, were able to perform the steps required to use our
smartphone dongle to replicate a laboratory-based immunoassay. During our study, reading
comprehension was a limiting factor, however, this could be obviated by incorporating audio
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instructions and video demonstrations. Between the first and second sets, 4 steps showed
significant improvement: pulling the lancet tip off, collecting blood into part A, connecting
part A and B, and inserting chip fully into the device. The training improvement on these
steps demonstrates that our steps are simple enough to perform, and each of the issues
encountered can be mitigated through engineered solutions. To increase usability, we found
that steps with more feedback were easier to perform. For example, pressing the switch
(step 12) gave an audible click that signaled that the step had been completed correctly.
Similarly, steps such as inserting the cassette are ambiguous, and providing a feedback
to the user (a light or a click when fully inserted), would ensure that certain steps get
completed. Connecting Part A and Part B could also incorporate an audible click to indicate
completion of the step. While these are improvements that are typically relegated to ”product
development”, understanding the important constraints can drive relevant innovation at the
very beginning of research. With simple engineering improvements, we demonstrate that
there is potential to expand access to laboratory-based diagnostics to anybody with access
to the smartphone and our device.
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Chapter 6
Material selection for an amplification
module for use in molecular
diagnostics
6.1 Background
Molecular diagnostics represents the second major class of diagnostic methods for
infectious diseases. They can be used to diagnose early infant infections (such as for HIV),
diseases that do not have a broadly expressed antibody (such as dengue), or infectious
organisms that are difficult to culture (such as tuberculosis). Polymerase chain reaction
(PCR) has become a mainstay for almost every diagnostic laboratory in the United States,
however, most laboratories in the developing world are still lacking. It uses a heavy power
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load, requires refrigerated ingredients, extremely clean working environment, pipettors, and
skilled personnel. Currently, most molecular diagnostics is sent to centralized laboratories,
and diagnoses can take days or weeks to return to the patient.
Many academic efforts in microfluidic often utilize polydimethylsiloxane (PDMS), one
of the most popular materials due to ease of prototyping with soft-lithography. However,
this presents a challenge when translating academic innovations to industry, as PDMS does
not provide the ecomonies of scale as with other methods, such as injection molding [77].
Further, the design of microfluidic devices is highly on material and surface properties (such
as elasticity, surface roughness, porosity, methods for coating), so developing designs in an
ultimately un-manufacturable material may render many academic innovations unable to be
translated [78]. There have been numerous academic endeavors to perform nucleic acid ampli-
fication in microfluidic format [79, 80]. Many attempts have been in traditional microfluidic
materials of glass, silicon, and PDMS. While these are amenable to traditional methods and
techniques familiar to microfluidic laboratories, these fabrication methods are not often very
high throughput, and have difficulty translating outside of the laboratory. Many solutions,
while functional, include coated glass [81], PDMS devices [82], and integrated sensors and
electrodes [83], that do not lend themselves to low-cost or mass manufacturability.
By contrast, injection molded thermoplastics are easily mass manufactured, easily
reproducible, and a viable material for developing microfluidics. There are three main meth-
ods for prototyping microfluidics in plastics [84]: 1) Computer-numerical control (CNC)-
micromilling. This method uses a rapidly rotating cutting tool (endmill) to cut away at a
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Figure 6.1: Table comparing plastic manufacturing methods: CNC micromilling, hot em-
bossing, and injection molding. Adapted from [84].
workpiece, in this case a sheet of plastic. The workpiece is attached to the worktable which
moves in the x-y direction under the endmill, and the endmill moves in the z direction as it
continues to cut the desired design. This method lends itself to fast iteration and therefore
is great for research-level prototyping, however is not a high-throughput method of manufac-
ture for industry. Because the plastic pieces are being cut, the surface roughness from this
method is the highest of all three methods. While it does not match injection molding in
surface roughness or throughput, CNC micromilling can be a good method for fast protop-
tying in plastics and testing the microfluidic design for material chacteristics beyond surface
roughness (e.g. elasticity, porosity). 2) Hot-embossing. This method uses a metal mold to
emboss a microfluidic design into a sheet of thermoplastic. The plastic and metal mold are
heated to the glass transition temperature of a particular thermoplastic and put under high
pressure to create the design. The surface roughness of the plastic piece is proportional to
the roughness of the mold. Metal molds can be micromilled, and electroplated for additional
smoothness. This method more closely replicates injection molding in its surface roughness
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and therefore is one of the best in-house prototyping methods for manufacturable plastics. 3)
Injection molding. In this method, thermoplastic pellets are fully melted (in contrast to hot
embossing, which only heats to glass transition temperature), and injected at high pressure
into a heated metal mold. Metal molds are milled and electroplated for minimal surface
roughness. This is the preferred method of mass manufacturing thermoplastics in industry,
and difficult to replicate at the academic level without expensive and specialized machinery.
Recently, some companies (Proto Labs, 3Dsystems) provide low-volume (thousands) and
fast-turnaround injection molding for prototyping to bridge the gap between research-level
prototyping and large-scale manufacturing.
Integrating design parameters that are suitable for scale-up ensure that principles and
concepts developed in the laboratory are able to be translated out of the laboratory. In this
work, we study the use of polycarbonate as a material in an amplification chamber for PCR.
Polycarbonate (PC) is a commonly found thermoplastic that has a high glass transition
temperature (135◦C), above that of the highest temperature used in PCR (95◦C). While
polypropylene is another commonly used plastic for commercially bought PCR tubes, they
have been observed to deform after use (and therefore not suitable for a robust microfluidic
design). Further, we chose polycarbonate for its overall optical clarity (in comparison to
polypropylene), which will be important for downstream optical detection of amplicons.
While polycarbonate has been used in microfluidic PCR devices, a wide range of fabrication
and surface treatment methods have been reported [79, 80], with no clear comparisons on
robustness or effectiveness of the various methods. In particular, we study its interactions
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with the PCR reaction solution, and methods to increase the robustness of PCR reactions
within thermoplastic devices.
6.2 Methods
6.2.1 Amplification chip fabrication
Polycarbonate plastic (3mm) was purchased through McMaster-Carr. Milled plastic
chips were designed in Solidworks and Mastercam, fabricated on a CNC mill, with inlet and
outlet holes created using a hand pressed drill. Embossed plastic chips were hot embossed
at 130◦C, 1000 psi, with inlet and outlet holes created within the mold, and a thin layer of
remaining plastic was cleared with a thin needle. Plastic chips were sealed by spreading a
small volume of acetonitrile onto the chip surface (though not within the cavity), and placing
a thin (0.25mm) piece of polycarbonate on top with manual pressure. Excess acetonitrile
was expelled from the cavity with compressed air immediately afterwards. After loading
with PCR mix, inlets and outlets were sealed with Microamp adhesive (Life Technologies),
typically used to seal RT-PCR plates. Chamber surfaces were coated with bovine serum
albumin (BSA, Sigma) by filling the chamber with BSA solution and incubating at room
temperature for 2 hours and subsequently extracting the fluid. Chambers were coated with
Sigmacote (Sigma) by filling the chamber with Sigmacote and immediately extracting the
fluid. Teflon solution (1% w/v in Fluorinert, Sigma) was dissolved on an end-on-end mixer
over 4 days. To coat, 1% Teflon solution was inserted into the chamber, placed in a vacuum
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chamber to evaporate solvent, and repeated. Where indicated, plastic pieces were vapor
polished with acetonitrile. A shallow dish of acetonitrile was heated on a hotplate at 60◦C,
plastic pieces were placed atop the dish, facing downwards to be within th6e direct line of
the vapor. Pieces were polished for 2-3 rounds of 15 second treatments, and allowed to dry
in the oven to remove any remaining solvent.
6.2.2 Thermocycler for amplification chip
An Arduino was programmed to control power to a thermoelectric cooler (TEC,
Custom Thermoelectric) based on feedback from a thermocouple within the chip. Once the
thermocouple sensed the TEC had reached a target temperature, it would alternately switch
on or off to maintain the temperature for each phase of the thermocycling reaction. We
used a fast PCR thermocycling reaction with 35 cycles of 94◦C for 5 seconds, 62◦C for 25
seconds, and a final elongation phase of 72◦C for 20 seconds. The thermocouple was placed
in a chamber immediately beside the reaction chamber.
6.2.3 Polymerase chain reaction (PCR)
Polymerase chain reaction consisted of: 11.5 µl RNAse free water, 2µl 10x buffer,
1.6 µl dNTP, 2.4 µl MgCl2, 1 µl of primers, 1µl of Taq polymerase, and 0.5µl of purified
genomic Mycobacterium tuberculosis DNA(0.5µl of RNAse free water for negative control).
We used primers for M.tuberculosis gene IS6110, with a forward primer (5-GAG CGT AGG
CGT CGG TGA CAA AGG-3), reverse primer (5-GCT TCG GAC CAC CAG CAC CTA
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ACC-3), yielding an amplicon length of 105bp. Tabletop thermocycling was performed on
a Biorad T100. Amplification products were run a 2% agarose gel and visualized on a UV
imager (Gel Doc-it, Bioscience Technology). Band intensities were quantified by measuring
mean band intensities in Adobe Photoshop.
6.3 Results
6.3.1 Surface roughness of plastics
We first wanted to study the effect various manufacturing methods for plastics. We
suspected surface roughness and properties were critical in the material surface interaction,
so we created polycarbonate pieces with different levels of surface roughness. Each piece
was fabricated using the method described (cut thin film, sanding, sawing, milling, milling
and polishing). Each piece was cut to approximately 1mm x 1mm x 1mm, to standardize
effects of additional volume within the PCR reaction tube. Once fabricated, each piece was
cleaned with bleach, sonicated for 5 minutes in RNAse free water (twice), and dried with
compressed nitrogen. The pieces were then placed with clean tweezers into the reaction tube
with the PCR mastermix (20 µl total volume). Polycarbonate film showed only a slight
decrease in reaction efficiency, potentially due to volume effects of the piece in the reaction
chamber (Figure 6.2). It demonstrates that PC as a material does not inhibit PCR, and
serves as a baseline for the other pieces, as its surface is expected to be smooth and inert.
As expected, sanded and sawed PC decreased reaction efficiency significantly, potentially
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Figure 6.2: Band intensities of amplification products in the presence of polycarbonate
pieces. Intensities are normalized against the negative and positive control for each experi-
ment.
binding key proteins or nucleic acids. Milled PC with slightly lower surface roughness showed
slightly better reaction efficiency. Interestingly, the polished polycarbonate matched if not
exceeded the reaction efficiency of the PC film, showing a functionally smoothed surface, and
a promising fabrication and processing method for future microfluidic amplification devices.
6.3.2 Enzyme inactivation
We next wanted to understand the source of reaction inefficiency from our plastic
thermocycler. We tested a PCR reaction mixture heated inside the plastic thermocycler
at 94C for 5 min, approximately the total time at the highest heating temperature. After,
we extracted the mixture and placed it in a commercial thermocycler to see if the reaction
mixture was still active. If the source of inefficiency was from poor temperature control alone,
we would expect to see significant amplification, close to the positive control. Next, to test if
the Taq polymerase enzyme was the culprit for reduced reaction efficiency, we tested a PCR
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reaction mixture heated inside the plastic thermocycler at 94C for 5 min, added another 0.5
muL of enzyme solution (0.5 IU), then placed the mixture in a commercial thermocycler.
We found that adding enzyme effectively increased reaction efficiency (Figure 6.3). This
suggests that the enzyme is either adhering to the plastic surface or becoming inactivated
due to poor temperature control (temperature too high).
Figure 6.3: Normalized band intensities when 1) a PCR reaction mixture is run in plastic
thermocycler and then transferred to a commercial thermocycler, and 2) a PCR reaction
mixture is run in a plastic thermocycler, additional enzyme is added then the mixture is
transferred to a commerical thermocycler (n=2).
6.3.3 Temperature control in the plastic amplfication chip
We milled a plastic chip for thermocycling; it includes an oval chamber that is 1.58
mm wide, 5.5 mm long, 1 mm swwp for a total volume of approximately 10 µl. There is a
slot beside the chamber for a temperature sensor, that provides feedback to the Arduino to
CHAPTER 6. MATERIAL SELECTION FOR AN AMPLIFICATION MODULE FOR
USE IN MOLECULAR DIAGNOSTICS 99
control power to the thermoelectric couple (Figure 6.4 and 6.5).
Figure 6.4: Schematic diagram of plastic chip and thermocycling set-up.
Figure 6.5: Photograph of CNC milled PCR chamber.
The sensor placed to the side of the thermocycling chamber is used as feedback to
the heater. It is meant to be a surrogate for the temperature inside the chamber, however,
there was found to be a 20◦C difference in temperature between the temperature inside the
chamber and the temperature sensed by the side-sensor (Figure 6.6 and 6.7). This is likely
due to the fact that the side-sensor is not immersed in liquid and may have closer contact
to the TEC, allowing for more sensitive measurements of heater temperature. Given this
disparity, there is a significant need to calibrate the chamber-side on-heater sensor to the
actual temperature within the chip.
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Figure 6.6: Schematic diagram of temperature comparison experiment.
As a result, we changed the overall chip design to accomodate a shallower chamber
(400 µm tall), with an insert for a thermocouple to sit directly on the heater, sealed with
kapton tape (Figure 6.8). With the shallower chamber, temperatures experienced inside
the chamber matched the heater temperatures much more closely, allowing for more precise
control of in-chamber temperatures (Figure 6.9).
6.3.4 Bubble formation
Also, significant in the development of microfluidic PCR is bubble formation within
the chamber. As the fluid gets heated very close to boiling point, any microbubbles in the
fluid enlarge creating uneven heating inside the chamber (affecting amplification efficiency)
and also can enlarge to the point of expelling the PCR mix out of the chamber. This is
particularly evident with plastic devices as plastic is hydrophilic, and any surface roughness
can be a point for microbubble formation. To mitigate bubble formation, we introduced
PCR-compatible mineral oil into the chamber immediately prior to introducing the PCR
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Figure 6.7: Comparison of temperature inside the chamber compared to temperature
sensed by the chamber-side sensor.
master mix and introduced both fluids with a syringe pump set to 10µl/min. In all conditions
with the mineral oil, reduced bubbles were observed, even when heated to 90◦C (Figure 6.10).
6.4 Discussion and conclusions
Significant progress must be made in the understanding of plastics as a material for
microfluidic devices. Many innovations in the literature remain as successes in the laboratory
since their design parameters may not meet easily manufacturable standards. Increasing
literature surrounding the specific interaction of key biological reactions (such as PCR) with
plastics, will allow for easier development of plastic devices at the research phase. This work
helps us begin to understand how certain material surface properties, adsorption properties,
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Figure 6.8: Photograph of top view of PCR double chamber configuration with thermo-
couple directly on top of TEC.
and schemical leeching, interact with the PCR reaction and surface coatings that may aid
PCR efficiency. Additionally, we begin to explore the challenges of efficiently heating a
plastic chip, given its low heat transfer coefficient, particularly compared to glass or silicon.
Further work will be necessary to gain robust and repeatable temperature control
within the chamber without the need for a thermocouple within the reaction chamber or
the plastic chip. Power consumption of the system will have to be reduced, as it currently
is infeasible for a battery-powered point-of-care format. Ultimately, this module could be
incorporated with sample processing and amplicon detection modules previously developed
in our lab. The integrated design would be mindful of critical design constraints of low-
resource settings: low-cost manufacturing, robust design, low-power consumption, and fully
automated steps.
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Figure 6.9: Comparison of temperature inside the chamber compared to temperature
sensed by the chamber-side sensor with shallow chamber design.
Figure 6.10: Photograph of improved amplification chamber design. Each chip has two
chambers, in each image the right chamber was filled with mineral oil before colored buffer
was introduced into the chamber. The left picture shows the chamber at room temperature,
while the right picture shows the chamber at 90C, showing mineral oil effectively reduces
the generation of bubbles.
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Chapter 7
Conclusions
In this dissertation, we examine several stages of translational engineering. Microflu-
idics has always promised the potential for miniaturized point-of-care technologies, and this
dissertations takes pratical steps towards achieving this.We first develop an integrated device
that fulfills the operational constraints and clinical needs of operating in a resource limited
setting (Chapter 2, Chapter 3). We then test this device under real-world conditions with
local healthcare workers (Chapter 4) as well as patient participants with no healthcare back-
ground (Chapter 5). By testing in the field, we gain true information on how well our device
fulfills design constraints at the intended setting, as well as invaluable insights into how users
value it. Lastly, we take insights from developing integrated and translatable technologies
back to the research level, initiating design with practical manufacturable materials (Chapter
6).
As we move towards translating technologies to impact human lives, there are several
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additional non-technical considerations that must be understood for successful implementa-
tion into the real world.
Regulatory approvals. A major hurdle in moving innovations from research to
product is regulatory approvals. Depending on the intended application, this means approval
through the Food and Drug Administration (FDA) for application in the US, CE Mark
for application in Europe, or the World Health Organization (WHO) for application in
developing countries. Each of these have standards on reproducibility of manufacturing
disposables (in our case plastic test cassettes), reproducibility of hardware (both intra-device
and inter-device readings), stability, to name a few. Often academic proof of concept level
innovations may not delve into these factors, and often will push these considerations off
to future work. However, designing solutions that have the potential to be repeatable and
testing for stability are important to consider starting at the research phase [13].
Integration into the healthcare system. One of the largest advantages of using
the mobile phone for decentralizing health is its ability to connect, through SMS, wifi, or
mobile web access. A device that provides a diagnosis is just one part of the health-care
continuum, and a mobile phone has the potential to provide linkage to care within the
healthcare system (Figure 7.1). Additionally, understanding how a device fits within the
healthcare continuum, what population it is intended to affect, how it fits into the current
healthcare system can provide insight into the cost-efffectiveness of a new intervention.
Patient privacy. As we move towards decentralizing health services through mobile
phones, patient privacy becomes an increasingly relevant concern. Fortunately, mobile health
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Figure 7.1: Schematic diagram of modes of entry an exit within the healthcare system
for an HIV diagnosis. The dark gray box indicates the intended point of intervention for
our diagnostic device, and light gray boxes indicate potential points of influence through a
mobile-connected diagnostic.
applications can utilize many of the existing encryption standards for electronic medical
records. First, there exist HIPAA compliant data transmission encryption standards to send
information between mobile phones and between a mobile phone and a centralized server.
Second, centralized servers can be encrypted and protected with the same standard as all
hospital servers. Lastly, de-identifying patient data gathered through the application can
protect patient privacy while providing health providers with valuable epidemiological data
to better understand and service patient needs. There will always exist a risk of hacking and
loss of privacy through mobile health applications, as with personal emails, online banking,
etc, however, we believe that the majority of consumers will take this risk for the benefit of
increased ownership and convenience surrounding one’s own health information.
Successful translational biomedical engineering requires a very interdisciplinary un-
derstanding of medicine, biology, materials science, electrical engineering, public health,
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business, and economics, to name a few. Interdisciplinary teams and perspectives allow for
the greatest chance for success.
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